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General introduction 
 
Chapter 1 
In the eighties and early nineties of the last century, acute hepatitis occurred in 5-10% of 
patients receiving  blood transfusions in the USA (1), and in more than 90% of cases this 
could not be attributed to hepatitis A or B (“Non-A, Non-B hepatitis”) (2). More than 50% of 
the hepatitis infections became chronic, and Non-A, Non-B hepatitis led to liver cirrhosis in 
about 20% of patients, thereby being a serious health burden (3). In 1989 the hepatitis C 
virus was discovered as the major cause of this post-transfusion hepatitis, but it was also 
found in many cases of unknown chronic hepatitis without known blood contacts in the past 
(sporadic HCV). It is estimated that more than 170 million people are infected with hepatitis C 
worldwide (4–6), leading to more than 280.000 deaths each year due to decompensated liver 
cirrhosis and liver cancer (7). 
 
Acyclovir and prednisone were not effective for chronic NANB hepatitis (8,9).  A  pilot study 
in 10 patients suggested that  interferon-alpha could be a potential therapy for chronic 
hepatitis C (10). Interferon  was proven to be effective in controlled trials  published in 1989 
(11,12). Based on these 2 studies, with 166 and 41 patients, respectively, Interferon (IFN) 3 
mega units (MU) thrice a week (tiw) for 6 months was registered as standard therapy in 
many countries around the world. 
 
Standard IFN treatment of chronic hepatitis C was hampered by two major problems: only 
50% of patients had disappearance of liver inflammation during treatment, expressed as 
normalization of the liver enzyme alanine amino transferase (ALT), and more than 50% of 
those with normal ALT levels during treatment had a relapse after treatment withdrawal, 
leading to less than 20-25% sustained ALT response 6 months after the end of treatment 
(11).  
 
These results led to an initiative in 1990 by physicians and basic scientists in Belgium, the 
Netherlands and Luxembourg (BeNeLux) to start investigator initiated studies aiming to 
unravel the mechanisms of non-response and to improve the success rate of treatment. The 
importance of designing studies based on virological in stead of biochemical assessments 
was recognized, and basic scientists worked hard to develop reliable HVC RNA assays 
which could be used in a standardized way in the clinical trials. It was understood that the 
important issues to study were initial non-response to therapy, breakthrough during treatment 
after an initial response, and relapse after treatment withdrawal. It was realized that large 
cohorts were needed to study treatment of these components in a randomized way, and with 
this aim the Benelux multicenter study group for treatment of chronic hepatitis C was formed. 
In this group, coordinated from Rotterdam, almost all academic centers from Belgium, 
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several academic centers from the Netherlands, and many large non-academic centers from 
the three Benelux countries were involved.   
 
From the start the aim was to closely cooperate with basic scientists, in particular virologist, 
molecular biologists and immunologists. The evolving techniques for qualitative and 
quantitative HCV RNA testing and analysis of HCV RNA genotypes were incorporated in the 
Benelux studies from the early days onward. The associated laboratory investigations and 
exploratory follow-up studies have been described in separate academic theses (van Doorn, 
Kleter) (13,14) and publications (15–20). Aims of the basic clinical studies were to make 
individualization of treatment possible and to reduce the incidence of initial non-response, 
breakthrough and relapse, by determining predictors and subsequently adapting the dose or 
duration of treatment. The concepts emerging from those studies were finally tested in a 
group of patients considered difficult to treat (21-23). This series of investigations led to 
another academic thesis (Bekkering) (24). 
 
This thesis describes a period of 10 years in which the treatment of chronic hepatitis C 
developed from occasional sustained response to cure in more than 60% of patients. 
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ABSTRACT 
 
In an interim analysis of the Benelux trial, no difference in alanine aminotransferase 
normalisation has been found between the high (6 million units) and standard (3 
million units) doses of interferon alfa-2b during the first eight weeks of treatment. The 
probability of achieving normal alanine aminotransferase activity on at least two 
successive occasions during treatment is 65% for the standard dose and 73% for the 
higher dose. Measurement of plasma hepatitis C virus-RNA suggests that hepatitis C 
virus-RNA negativity after four weeks of treatment is a prerequisite for sustained 
response to interferon alfa-2b. 
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INTRODUCTION 
 
A standard six month course of treatment with alpha interferon, 3 million units thrice 
weekly, leads to alanine aminotransferase normalisation in about 50% of patients 
with hepatitis C virus infection. Relapses occur in most of the patients, however, after 
treatment is stopped. So, conceivably, treatment results might he improved if a 
higher induction dose is used and if the dosage and duration of treatment are attuned 
to the effects on alanine aminotransferase and hepatitis C virus-RNA.  
 
METHODS  
 
Patients were included in the Benelux multicentre trial if they had: (a) history of 
alanine aminotransferase ≥2 times the upper limit of normal, for at least six months; 
(b) history of exposure to blood products or a positive anti-HCV test; (c) no clinical, 
histological or serological evidence of other viral, alcoholic, drug, or obesity related, 
hereditary or autoimmune hepatitis. Patients were randomised to receive either: (a) 
standard treatment; 3 million units interferon alfa-2b (INTRON A) thrice weekly for 24 
weeks; (b) experimental treatment: induction phase of 6 million units interferon alfa-
2b thrice weekly for eight weeks, followed by a maintenance phase of titrated doses 
of interferon 6 to 1 million units thrice weekly until biochemical and virological 
remission (alanine aminotransferase activity normal, plasma hepatitis C virus-RNA 
undetectable) was achieved while on 1 million units thrice weekly. Interferon was 
given by subcutaneous injection. Treatment was withdrawn in cases of non-response 
after 12 weeks, or after 52 weeks in cases of partial response.  
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RESULTS 
 
To date, 244 patients with hepatitis C virus have been entered into the study. Patient 
characteristics before treatment are comparable with the standard and experimental 
treatment group (Table). No statistically significant differences were seen between 
the groups by either χ square or Wilcoxon's rank sum test.  
 
Data for 12 weeks are available for 188 patients and 149 patients have been followed 
for at least six months. No difference in alanine aminotransferase normalisation rate 
has been found between the high (6 million units) and standard (3 million units) 
induction dose during the first eight weeks, with figures of 53% (95% confidence 
intervals 46,66) and 54% (95% confidence intervals 44,64), respectively.  
 
 
Table  Patient characteristics before treatment 
 Interferon treatment schedule 
 Standard 
(n=120) 
Experimental 
(n=124) 
Men/women 74/46 69/55 
Blood exposure 74 79 
Anti-HCV positive 116 120 
Age* 47.1 (14) 46-7 (14) 
Alanine aminotransferase (IU/l)* 168 (98) 150 (91) 
Hepatitis C virus-RNA positive† 24/27 37/39 
Histological examination 
 Chronic persistent hepatitis 
 Chronic active hepatitis 
 Cirrhosis 
 
20 
65 
21 
 
28 
64 
30 
 
*Mean (SD).  
†Tested in 66 patients only.  
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The probability (actuarial analysis) of reaching normal alanine aminotransferase 
activity on at least two successive occasions during treatment is 65% (95% 
confidence intervals 56,74) for the standard scheme and 73% (95% confidence 
intervals 64,82) for the experimental scheme, with a plateau after 16 weeks (NS).  
The plasma hepatitis C virus-RNA has been measured in a subgroup of the first 
consecutive 24 patients from one centre, and studied sequentially to evaluate 
whether a long term treatment response could be predicted early. Fifteen patients 
had detectable hepatitis C virus-RNA at four weeks' treatment despite alanine 
aminotransferase normalisation in seven. All 15 remained viraemic until the end of 
treatment (six months), 13 of them with raised transaminase activity. Nine of the 24 
patients had undetectable hepatitis C virus-RNA at four weeks while seven remained 
hepatitis C virus-RNA negative until the end of treatment. These results suggest that, 
when hepatitis C virus-RNA is detectable after four weeks of interferon treatment, it is 
predictive for long term non-response. Hepatitis C virus-RNA negativity after four 
weeks of treatment with interferon seems to be a prerequisite for a sustained 
treatment response. The hepatitis C virus-RNA value at four weeks is of more 
importance than alanine aminotransferase activity in predicting the long term 
treatment response (p<0.001, Fisher's exact test). 
 
CONCLUSIONS 
 
High dose induction treatment (6 v 3 million units alpha interferon thrice weekly) does 
not improve the early response rate. Hepatitis C virus-RNA determination at four 
weeks' treatment seems to be highly predictive for long term treatment outcome. 
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ABSTRACT 
 
Background In an attempt to improve the limited efficacy of treatment of chronic 
hepatitis C with interferon-alpha 3 MU tiw, we studied the effects of double-dose 
therapy followed by downward titration, and analyzed the pre- and pertreatment 
factors associated with response or non-response. 
Methods 354 consecutive patients in 19 centres were randomized to interferon-alpha 
3 MU tiw for 6 months or 6 MU tiw for 8 weeks followed by down-titration (3,1 MU tiw) 
till alanine aminotransferase remained normal and plasma HCV RNA was repeatedly 
undetectable. The primary outcome measure was sustained alanine 
aminotransferase and HCV RNA response 6 months after treatment. 
Results 336 patients received treatment. The sustained response rate for patients 
receiving 3 MU tiw for 6 months was 14% (9-21%) and for patients receiving double 
dose tiw for 8 weeks and thereafter titrated therapy 15% (10-21%) (p=0.8). 
Pretreatment factors associated with a sustained alanine aminotransferase plus HCV 
RNA response were the absence of cirrhosis, presence of genotype 2 or 3, a low 
viral load and, in addition, a low alanine aminotransferase/aspartate 
aminotransferase ratio; a model was developed to allow estimation of the chance of 
response for the individual patient. The most powerful predictor of sustained 
response, however, was plasma HCV RNA at week 4; a positive test virtually 
precluded a sustained response (1.7%, 0.4-5.0%). If week 4 HCV RNA was not 
detectable, the chance of a sustained response was 21% (12-34%) for genotype 1 
versus 40% (28-54%) for the others (p=0.02). Six MU tiw led to a significant higher 
week 4 HCV RNA response (47% not detectable) than 3 MU (37%) (p=0.02). During 
down titration this difference in viral on-treatment response was lost. 
Conclusions In the treatment of hepatitis C, an early HCV RNA response is a 
prerequisite for long-term efficacy. Doubling the initial interferon dose increases this 
early response, but subsequent downward titration negates this effect, especially in 
genotype 1. 
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INTRODUCTION 
 
Chronic hepatitis C can be modified by interferon-alpha therapy (1). Most large 
studies have used the serum alanine aminotransferase (ALT) level as the primary 
marker to assess the efficacy of treatment. Sustained ALT normalization 6 months 
after therapy is only found in 15-30% of patients (2,3). The apparent need for 
enhancing the efficacy of therapy has been addressed in many randomized 
controlled trials assessing modifications in dose and duration of therapy. 
Prolongation of therapy increases the ALT sustained response rate (4,5). The role of 
the interferon dosage beyond 3 million units (MU) thrice weekly (tiw) is still uncertain, 
and further improvement in treatment efficacy is hampered by the lack of knowledge 
of the viral mechanisms involved in response. This report of the Benelux Study 
Group on treatment of chronic HCV with interferon-alpha describes the results of a 
randomized controlled trial in 336 patients, with special emphasis on evaluation of a 
double IFN dose initially, treatment monitoring by ALT and HCV RNA, and analysis of 
pretreatment and early virological on-treatment factors associated with response. 
 
MATERIALS AND METHODS 
 
Patients 
Patients between 18 and 70 years of age were eligible for the study if they had a 
positive blood test for anti-HCV or documented chronic non-A, non-B hepatitis after 
receiving blood products, serum ALT concentrations at least twice the upper limit of 
normal for at least 6 months and liver biopsy findings compatible with chronic 
hepatitis. Patients were excluded in case of additional causes of chronic liver 
disease: presence of hepatitis B surface antigen, more than 150 grams ethanol per 
week, ferritin >1000 µg/l, auto-antibodies >1:100. Further exclusion criteria were 
previous antiviral therapy, immunosuppressives, decompensated liver disease 
(ascites, bleeding varices, encephalopathy, bilirubin >34 µmol/l, albumin <32 g/l, 
serum creatinine >140 µmol/l), cytopenia (platelet count <50x109/l, granulocytes 
<1.5x109/l), coinfection with HIV or signs of hepatocellular carcinoma. 
The study was approved by the institutional review board of each participating centre; 
written informed consent was obtained from each patient. 
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Treatment 
Patients were randomized at a ratio of 4:5 to receive either “standard dose” or 
"titrated dose” treatment. Randomization was performed centrally by opening an 
envelope (6). Standard dose treatment consisted of 3 MU of recombinant interferon 
alpha-2b (Intron-A, Schering-Plough, Kenilworth, N.J., USA) injected subcutaneously 
tiw for 24 weeks. Titrated dose treatment started with 6 MU of interferon alpha-2b tiw 
for the first eight weeks, followed by dose reduction to 3 and 1 MU tiw at intervals of 
at least 8 weeks, provided that ALT levels remained normal; treatment was ended 
when ALT levels remained normal and HCV RNA remained undetectable by PCR for 
at least 8 weeks of 1 MU tiw; treatment was discontinued because of failure if ALT 
did not normalize during 6 MU tiw, or after 52 weeks if ALT normalized but HCV RNA 
remained detectable. 
Blood was sampled at 4-week intervals during treatment and 6-week intervals during 
follow-up. The interferon dosage was reduced to 50 percent in case of leukopenia 
(<1.5 x 109/l) or thrombocytopenia (<50x109/l) or when severe subjective side-effects 
persisted. Hematologic and biochemical tests were performed in the certified 
laboratories of the participating hospitals; results were corrected for local normal 
values. 
 
Virologic assessments 
Blood samples for HCV RNA determinations were taken under strict conditions to 
avoid cross-contamination or breakdown of RNA. Special tubes and pipettes were 
provided, and samples were processed to plasma and frozen to -70 oC within 2 h of 
collection. All virologic assessments were performed in the Department of Virology in 
Rotterdam. Plasma HCV RNA was analysed in duplicate by the polymerase chain 
reaction (PCR) using two sets of primers derived from the 5' noncoding region, 
followed by a hybridization assay, as described previously (7). The PCR assay tested 
faultless in the Eurohep proficiency panel (8), with a sensitivity of 0.9 x103 genome 
equivalents per millilitre (geq/ml) for genotype 1 and 1.2 x103 geq/ml for genotype 3. 
The amplification products were used in the Line Probe Assay (Inno-LiPA, 
Innogenetics, Ghent, Belgium) for assessment of the genotype. The genotype was 
also determined by direct sequence analysis for the first 60 patients and in case of an 
indeterminate LiPA result. The major HCV types (1–5) were classified correctly by 
LiPA in all cases; HCV subtype 1a and 1b were misclassified in 8% of cases (9). 
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Quantification of plasma HCV RNA was performed by branched DNA assay 
(Quantiplex v 1.0, Chiron, Emeryville, CA, USA). The detection limit of this assay was 
0.35 x106 genome equivalents per millilitre. Results of this first-generation bDNA 
assay were corrected by a factor 3 for genotype 2 and a factor 2 for genotype 3, 
according to recent guidelines (10). 
 
Liver Histology 
Liver specimens, obtained before the start of therapy and after 6 months of follow-up, 
were reviewed by two pathologists who were blinded for all clinical information. 
Histological scoring was based on the original histological activity index by Knodell et 
al. (11), with a modification according to Desmet et al. (12) in which a distinction 
between ‘stage’ and ‘grade’ of chronic hepatitis was proposed. Stage (0–4) reflects 
the degree of fibrosis and architectural changes; grade (0–18) reflects the 
necroinflammatory activity. 
 
Response Criteria 
Response was defined according to the standards outlined at the recent NIH 
Consensus Development Conference (13,14) as virological and biochemical on-
treatment response (OTR), end-of-treatment response (ETR) and sustained 
response 6 months post therapy cessation (SR). Biochemical and virological 
responses were calculated both as separate items as well as combined. 
SR, which was the main outcome measure of this study, used to estimate the 
required sample size, was defined according to these guidelines as persistently 
normal ALT levels and undetectable plasma HCV RNA 6 months after the end of 
therapy. ETR was defined as the presence of normal ALT levels at the end of 
treatment and at least 1 month earlier, and no detectable HCV RNA. 
The biochemical on-treatment response was assessed at the end of the double dose 
induction period (week 8) and cumulative during therapy (ALT repeatedly normal on 
at least two occasions with at least 1 month interval). The virological on-treatment 
response (HCV RNA not detectable) was assessed at week 4 instead of week 8 
because of the earlier observation that the HCV RNA response precedes the ALT 
response by about 4 weeks (15). As a secondary outcome measure, the change in 
the histological inflammatory activity and grade of fibrosis was taken, and classified 
as ‘worsened’ (increase in severity of at least one point), ‘unchanged’ or ‘improved’ 
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(decrease of at least one point). 
 
Statistical Analysis 
Categorical variables were compared by the chi-squared test or Fisher exact test, 
and continuous variables by the Student t-test or the Mann-Whitney test, as 
appropriate. Cumulative response rates were calculated by the Kaplan-Meier method 
and compared by the log-rank test. Variables with p-values ≤0.2 in the univariate 
analysis were included in multivariate analysis. The independent prognostic value of 
the selected variables was determined by backward stepwise selection procedures 
by two independent persons, using SPSS software (SPSS Inc, Chicago, IL, USA) 
and Stata software (Stata Corp, Texas, TX, USA), yielding similar results; predictor 
variables for biochemical OTR (cumulative over time) were determined by Cox-
regression analysis, and predictor variables for virological OTR (week 4) and SR (6 
months after treatment cessation) by logistic regression analysis. ALT and HCV RNA 
concentrations were logarithmically transformed to obtain approximately normal 
distributions. In the multivariate analysis, continuous parameters were analysed by 
their actual values and after transformation to categories. The categories for age 
were predefined, those for biochemical parameters were based on equal group sizes. 
The two types of analysis led to the same conclusions; only the results for categories 
are shown because they are easier to interpret. Changes in histology scores for 
inflammation and fibrosis were compared using the Kruskal-Wallis test for paired 
data. 
All comparisons shown were based on the intention-to-treat method. All tests of 
significance were two-tailed; p-values below 0.05 were considered to be significant. 
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RESULTS 
 
Patient characteristics 
Between 1990 and 1993, 354 patients were recruited from 19 hospitals in the 
Benelux (Belgium, The Netherlands and Luxembourg); 159 were randomized to 
receive ‘standard dose treatment’ and 195 ‘titrated dose treatment’ (ratio 4:5). 
Eighteen patients were excluded because they did not fit the entry criteria: five had a 
false-positive anti-HCV test and 13 withdrew before the start of treatment. All 
remaining 336 patients were included in the efficacy analysis. 
Characteristics of the patient groups are given in Table 1; the two groups appeared 
well balanced, except for the pretreatment ALT and HCV RNA concentrations. To 
adjust for this imbalance, the study outcome was also calculated after correction for 
these variables using multivariate analysis. 
 
Treatment 
Ten patients withdrew from treatment and follow-up shortly after the start of therapy 
because of noncompliance; these were classified as non-responders. In addition, in 
four cases the protocol was violated because titrated instead of standard therapy was 
given; these patients were classified in the intention-to-treat analysis as if they had 
received standard therapy. Per-protocol analysis, with exclusion of these 14 patients, 
led to the same conclusions as the intention-to-treat analysis. Only the results of the 
latter are shown. 
The interferon dose was reduced or stopped because of side-effects in 16 patients 
(eight in each group). The mean duration of treatment (±SE) was 24 ±1 weeks for the 
group on standard dose therapy versus 38 ±2 weeks for the group on titrated dose 
therapy; the cumulative amount of interferon per patient was 219 ±6 million units in 
the standard dose versus 332 ±12 million units in the titrated dose group (p=0.0001). 
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Table 1  
Baseline characteristics of 336 hepatitis C patients treated with Interferon-alpha*  
Characteristic Standard dose* 
(n = 149) 
Titrated dose* 
(n = 187) 
Age (years) 47 ± 1.2 47 ± 1.0 
Male sex (%) 63 57 
History of parenteral exposure (%)a 62 65 
Time since parenteral exposure (years) 14 ± 1.2 12 ± 0.9 
Serum Alanine Aminotransferaseb 5.2 ± 0.3 4.4 ± 0.2 
Histological Activity Index 
  Grade of inflammation (0–18) 
  Stage of fibrosis (0–4) 
 
4.9 ± 0.2 
2.0 ± 0.1 
 
4.7 ± 0.2 
2.0 ± 0.1 
Cirrhosis (%) 25 25 
Genotype (%)c
  1a 
  1b 
  2 
  3 
  4 
  others 
 
6 
54 
11 
15 
4 
9 
 
9 
60 
8 
12 
5 
5 
Plasma HCV RNA concentrationd 5.2 ± 0.7 4.4 ± 0.5 
 
* Standard dose: 3 MU tiw, 6 months. Titrated dose: 6 MU tiw, 8 weeks, followed by dose 
reduction to 3 and 1 MU tiw, respectively. Values are means ± SE. 
a Parenteral exposure: transfusion, iv drug abuse, needle-stick accident. 
b Expressed as multiples of the upper limit of normal. 
c Assessed by INNO-LiPA in 322 patients. 
d Assessed by branched DNA (Quantiplex™ v 1.0) in 308 patients, expressed as multiples of 
106 genome equivalents per millilitre; a correction was made for genotype 2 and 3. 
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Biochemical and virologic responses 
The biochemical on-treatment response was similar for the two groups (Table 2). In 
contrast, the virological on-treatment response was higher in the 6 MU group: at 4 
weeks HCV RNA was not detectable in 45% versus 40% in those with 3 MU. This 
difference was significant after adjustment for imbalances in pretreatment 
characteristics by multivariate analysis (Table 3, odds ratio 1.9, p=0.017); the 
estimated HCV RNA response rate at 4 weeks after adjustment by multivariate 
analysis was 47% (95% C.I. 44–51%) for titrated therapy versus 37% (34–40%) for 
standard treatment. 
In both groups, most ALT relapses occurred after discontinuation of the 3 MU dose 
(titrated dose therapy: 20% relapse during 3 MU, 30% during 1 MU, 21% after end of 
therapy; standard dose therapy 18% during 3 MU, 53% after end of therapy). The 
initial difference in HCV RNA response between the two groups was lost during the 
process of downward titration, and six months after the end of treatment the groups 
had a comparable sustained ALT and HCV RNA response (14% vs 15%, p=0.8).  
Virtually all HCV RNA responses occurred within the first 4 weeks: 82% (75–88%) of 
all HCV RNA responses, including the temporary ones, and 94% (82–99%) of the 
HCV RNA responses which were followed by a sustained remission. During 
treatment, plasma HCV RNA remained detectable in about one-third of those with 
normal ALT levels, and the end point of ALT normalization with undetectable HCV 
RNA was significantly better for prediction of a sustained response (52%, CI 41–
62%) than the classical end point of ALT normalization alone (35%, 27–43%, 
p=0.01). 
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Liver Histology 
A pretreatment liver biopsy was obtained in 327 of 336 patients. Of the 327 
pretreatment biopsies, 287 could be retrieved and scored by two central pathologists. 
The local and central pathologists were in agreement on the presence or absence of 
cirrhosis in 87% of cases (kappa concordance 0.66). For analysis, classification by 
the central pathologists was used unless the biopsy was not available for review. 
Paired pre- and post-treatment biopsies could be evaluated in 126 cases. Patients 
with paired biopsies did not differ from the others with regard to pretreatment 
characteristics or response to treatment. A sustained response was accompanied by 
a reduction or disappearance of inflammatory activity in 96% of patients, whereas the 
inflammation was unchanged or worsened in 47% of those with a relapse or 
nonresponse (p<0.001). In addition, patients with a sustained response showed less 
progression of fibrosis (16%) compared to patients with a relapse (21%) or 
nonresponse (31%, p=0.05). After 6 months of follow-up, no significant differences 
were observed between the two treatment groups in changes in inflammatory activity, 
but the grade of fibrosis had increased more often among those who had received 
standard dose therapy (33%) than those with titrated dose therapy (16%) (p=0.04). 
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Features predicting response 
Responders to therapy were compared to non-responders for pretreatment clinical, 
biochemical, histological, and virological features. In accordance with other studies, 
independent predictors of both on-treatment and sustained response were the 
absence of cirrhosis, the presence of genotype 2 or 3 and a low plasma HCV RNA 
concentration. The pretreatment gamma glutamyl transferase (γGT) and ferritin 
levels, often mentioned by others, were independent predictors of a biochemical 
response (ALT), but had no relation to the effect on the virus (HCV RNA). An 
additional factor which proved to be an independent predictor of a sustained 
response was the pretreatment AST/ALT ratio, which predictive value was 
independent of the presence of cirrhosis. The logistic regression model for virological 
OTR and for biochemical plus virological SR (Table 3) could be simplified to a model 
including only the key factors cirrhosis, genotype and viral level without much loss of 
predictive power (ROC complete model 83%, simplified model 80%). This simplified 
model, which allows an easy estimate of the chance of response for the individual 
patient, is shown graphically in Figure 1.  
The most powerful predictor of the long-term outcome is the early on-treatment HCV 
RNA response. A positive HCV RNA 4 weeks after the start of treatment was 
followed by a nonresponse in 98.3% of cases, even though the ALT levels might be 
normal. This observation applies within all subcategories of pretreatment factors 
predictive of response (Table 4). For those in whom HCV RNA became undetectable 
at week 4, the only significant additional predictor of SR was the genotype 1: 
genotype 1 (subtype 1a or 1b) was present in 34% of those who remained in 
remission versus 56% in those who developed a relapse (p=0.02). 
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Figure 1        a 
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         b 
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Estimated probability and 95% C.I. of an early on-treatment virological response (a) and a 
sustained response (b) in relation to genotype, HCV RNA concentration (low: <0.35x106; 
medium: 0.35–2.6x106; high: >2.6x106 geq/ml), and presence or absence of cirrhosis. 
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Table 4 
Value of an early HCV RNA measurement for the prediction of a sustained response. 
 
Pretreatment  
category (n)  
% Sustained ALT and HCV RNA response  
(95%C.I.) 
 
  if HCV RNA week 4 
undetectable* 
if HCV RNA week 4 
detectable* 
Total group (336) 34 (26–43)  1.7 (0.4–5.0) 
AST/ALT ratio 
 <0.6 (168) 
 ≥ 0.6 (167) 
 
37 (26–47)  
28 (16–43)  
 
2.6 (0.3–9.0) 
1.0 (0.0–5.6) 
Cirrhosis 
 absent (246) 
 present (80) 
 
35 (26–44)  
25 (7.0–52)  
 
1.7 (0.2–6.0) 
1.8 (0.0–9.0) 
Genotype 
 1 (219) 
 others (117) 
 
21 (12–34)° 
40 (28–54)  
 
1.4 (0.0–5.0) 
2.9 (0.0–15) 
HCV RNA  (x106geq/ml)  
 <0.35 (52) 
 0.35-2.6 (128) 
 >2.6 (128) 
 
45 (27–64)  
31 (20–46)  
25 (12–42)  
5.0 (0.1–25) 
3.0 (0.4–11) 
0.0 (0.0–4.2) 
 
*Plasma HCV RNA 4 weeks after start of IFN treatment, assessed by a validated PCR 
(detection limit 0.9x103 genome equivalents per milliliter for genotype 1 and 1.2x103 geq/ml 
for genotype 3). 
°Genotype 1a or 1b versus others: p=0.017 (Chi2). 
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DISCUSSION 
 
In this large multicenter study, which aimed to compare two different treatment 
strategies, minimal effect on the final outcome was observed: in effect, the outcome 
was even more disappointing than usually published. Nevertheless, important new 
information emerged from the study which may help in the understanding of the 
factors associated with response and the design of more effective therapy. No effect 
of doubling the dose from 3 to 6 MU interferon tiw was found on the on-treatment 
response when assessed by ALT measurements (Table 2), which is in concordance 
with other reports (4,16–19). In contrast, after 4 weeks of therapy HCV RNA was 
significantly more often not detectable in those on 6 MU interferon tiw than in those 
on the standard 3 MU dose (odds ratio=1.9, p=0.017, Table 3), and this condition 
appeared to be a prerequisite for achieving a sustained response (Table 4). This 
observation supports further exploration of treatment schedules with higher dosages 
of interferon.  
 
The treatment end point of normal ALT levels and undetectable plasma HCV RNA 
was superior for the prediction of a sustained response (52%) compared to the end 
point of only ALT normalization (35%, p=0.01). In contrast to our initial expectations, 
the sustained response rate for the group on titrated dose therapy, which had an 
undetectable HCV RNA as end point, was not enhanced. We observed only a minor 
increase in the percentage undetectable HCV RNA with increased duration of 
interferon therapy. In fact 94% of the HCV RNA responses which were sustained had 
already occurred within the first 4 weeks. Loss of efficacy was observed by 
downward titration, which was associated with 20% breakthrough when assessed by 
HCV RNA (Table 2). Most studies suggest less breakthroughs during prolonged 
treatment with the standard 3 MU dose than with the 1 MU dose (4,5,20–23). 
Prolonged treatment with 6 MU might even be superior to 3 MU (18,24), which is in 
line with our observations on the early effect of the interferon dose on the HCV RNA 
response. 
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A sustained ALT and HCV RNA response was predicted in the present study by the 
absence of cirrhosis, the presence of genotype 2 or 3 and a low viral load (Table 3), 
which is in agreement with other observations (25-32). A new finding was the 
independent predictive value of the AST/ALT ratio, a clinical parameter thought to be 
associated with the presence of cirrhosis (33), but now apparently representing extra 
information in addition to that on cirrhosis in the prediction of a sustained response. 
An additional finding of multivariate analysis was the significant predictive value of 
serum ferritin for a primary ALT response but not for the primary HCV RNA response 
or the sustained ALT and HCV RNA response, suggesting that the iron content 
affects the inflammatory process but does not influence elimination of the hepatitis C 
virus. This might also explain the seemingly beneficial effect of iron depletion, when 
only the ALT levels are assessed (29). 
 
The large size of the study allowed us to construct a predictive model which has to 
be validated in a prospective way (Fig. 1). In this model the very low chance of 
sustained response for genotype 1 becomes clear, in particular in combination with 
cirrhosis, and also the very rewarding response for types 2 and 3 without cirrhosis.  
 
The observation that the HCV RNA response occurs soon after the start of therapy 
led us to analyse the value of HCV RNA assessment at 4 weeks of treatment as a 
time-dependent predictor of response. If HCV RNA is detectable, the chance of a 
sustained response is less than 5%; if HCV RNA is undetectable, the sustained 
response rate is on the average 34% (Table 4). Furthermore, determination of HCV 
RNA one month after start of treatment was superior in comparison with evaluation of 
baseline factors; only the genotype appeared to have additional prognostic value 
when the HCV RNA result at week 4 was known. If HCV RNA was undetectable at 
week 4, the sustained response rate was 21% for genotype 1a/b versus 40% for the 
others (p=0.017). 
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It is obvious that in view of the costs and adverse effects, interferon monotherapy 
should be restricted to those whose chances of a sustained response are 
appreciable; a response of 1 in 3 appears to represent a minimum. Continuation of 
therapy is then only suitable for those with undetectable plasma HCV RNA at week 4. 
For patients with an a priori low chance of a sustained response, for instance patients 
with cirrhosis who are clearly in need of antiviral therapy, interferon can be started 
and continued if HCV RNA becomes undetectable after 4 weeks. Once an early HCV 
RNA response has occurred, strategies need to be developed to diminish 
breakthrough and relapse. Avoidance of downward titration below 3MU tiw and 
maintenance therapy for 12 months are the first elements; whether the addition of 
other antiviral agents (ribavirin) is helpful is tested in ongoing investigations (34,35).  
Our study, however, clearly suggests that major advancements in treatment efficacy 
can only be made when the early HCV RNA response is enhanced, which might be 
achieved by increasing the initial interferon dose or dosing frequency (36). 
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Chapter 4 
SUMMARY 
 
Background/Aims In the early nineties, treatment of chronic hepatitis C with 
Interferon monotherapy led to a sustained response rate of about 15%. In this pilot 
study, we aimed to investigate the factors involved in non-response and to evaluate 
whether daily high dose Interferon could overcome part of the resistance to standard 
Interferon mono therapy. 
Methods Twenty-two patients with chronic hepatitis C who did not have an ALT 
normalization during previous treatment with Interferon 3–6 MU tiw were retreated 
with 10 MU daily for 5 days and 10 MU tiw until week 4, followed by stepwise dose 
reduction in case of initial HCV RNA response or dose withdrawal in case of non-
response.  
Results In retrospective, out of the 22 ALT non-responders, 13 were absolute HCV 
RNA nonresponders during previous treatment, 5 patients had a breaktrough and 4 a 
response-relapse. Sixty-eight percent had genotype 1, 59% a high viral load and 
65% had a cirrhosis. Fifteen patients (68%) did not respond to daily high dose 
retreatment, 3 (14%) had a response-relapse and 4 (22%, 95% C.I. 5–40%) had a 
sustained response. Sustained responders were characterised by absence of 
cirrhosis, virological breakthrough or response-relapse on previous therapy and 
undetectable HCV RNA at week 4. Although HCV RNA became undetectable during 
treatment in only 32% of patients, all patients had a drop in the level of viraemia 
during the first 2 weeks with a mean decrease of 2.6 log (99.7%).  
Conclusions Daily high dose retreatment of non-responders to interferon leads to 
additional sustained response. Dose-response observations suggest a variable 
sensitivity of HCV to IFN, and also other mechanisms involved in non-response. 
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INTRODUCTION 
 
In the early nineties, sustained virologic response after therapy of chronic hepatitis C 
was limited to around 15%, and in those groups who needed treatment most – like 
cirrhosis – a sustained response was only reached in about 5% of patients (1–3). 
Standard therapy consisted of interferon-alpha 3 MU tiw for 6 to 12 months. For 
those who did not respond to this treatment, two options were explored in the 
Benelux studies: daily high dose therapy (4) and combination therapy with Ribavirin 
(5). Because of the supposedly better efficacy and tolerability of combination therapy, 
the international research community focused in general on the latter, and reports on 
daily high dose therapy were neglected outside Japan.  
In this manuscript we report on the outcome of the clinical study with daily high dose 
interferon. Materials from this clinical study have been the basis for pioneer research 
on viral kinetics in chronic hepatitis C (6, 7). In addition, the marked drop in viral load 
observed both in genotype 1 and genotype non-1 patients, point to other 
mechanisms than drug resistance as cause of non-response.  
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MATERIALS AND METHODS 
 
Patients 
Twenty-two patients with chronic hepatitis C who did not respond to previous therapy 
were included in this pilot study. Non-response was originally defined as lack of 2 
sequential normal ALT’s at the end of treatment; HCV RNA was tested 
retrospectively. All subjects had been treated in a Benelux multicenter trial comparing 
standard IFN monotherapy (Interferon-alpha-2b 3 MU tiw for 24 weeks) with 6 MU tiw 
for 8 weeks followed by dose reduction based on ALT and HCV RNA response (3).  
Candidate for the high dose interferon treatment were all patients not responding to 
primary interferon treatment and in whom the diagnosis of hepatitis C was confirmed 
by detection of plasma HCV-RNA and exclusion of other causes of chronic hepatitis. 
Patients were eligible for high dose interferon treatment after withdrawal of interferon 
for at least 6 months. Overall entry and exclusion criteria were the same as described 
in the original protocol for the Benelux study (3). Patients with a high risk for serious 
or severe side effects were excluded: active cirrhosis with severe cytopenia (platelets 
<50 x 109/l, granulocytes <1.5 x 109/l); decompensated liver disease (ascites, bleeding 
varices, spontaneous hepatic encephalopathy, bilirubin >34 µmol/l, albumin <32 g/l, 
quicktest/normotestR less than 35%, serum creatinine >140 µmol/l); autoimmune 
diseases such as thyreoiditis and glomerulonephritis, or positive antinuclear, 
antimitochondrial, or smooth muscle antibody ≥1:100 dilution of serum; clinically 
important psychiatric illness; history of seizures; severe adverse events during the 
primary interferon treatment. 
 
Design of the study 
The study was designed in such a way that it made possible later assessment (when 
adequate techniques became available) of factors thought to be possibly involved in 
resistance to treatment, e.g. mutations of viral nucleotide sequences and changes in 
interferon induced pathways like induction of 2’5’-OAS and protein kinases, expression 
of HLA and activation of NK cells, alterations in interferon kinetics and viral kinetics. In 
three centers with appropriate laboratory facilities for direct preparation of blood 
samples 22 patients were included, and approximately 10 of them agreed to frequent 
blood sampling. The study was approved by the ethical committees of the university 
hospitals of Rotterdam and Gent, and all patients gave their written informed consent. 
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When sensitive and reliable techniques for assessment of quantitative HCV RNA 
became available, out of all possibilities mentioned above we focussed on assessment 
of viral kinetics. The results of these assessments led to several publications on viral 
kinetics in interferon mono therapy (6, 7). In this manuscript we report on the actual 
outcome of the study and address the question whether initial non-response to 
interferon can be overcome by daily high dose therapy. 
 
Treatment and assessments 
Patients were retreated with daily high dosage IFN therapy, consisting of daily 10 MU 
IFN-a2b sc. for 5 consecutive days, followed by 10 MU thrice weekly until week 4. 
Patients were allowed to withdraw for non-response in case HCV RNA remained 
detectable at week 4; in case of HCV RNA response IFN was tapered stepwise to 3 
and 1 MU tiw and ended when ALT remained repeatedly normal and HCV RNA 
undetectable during the lowest IFN dose. 
Patients were allowed to take up to 4 grams of paracetamol daily to reduce side 
effects. 
Blood was sampled for liver and haematological tests pre-treatment and every 4 weeks 
thereafter. HCV RNA was assessed before starting treatment, at week 4, at the end of 
therapy and 26 weeks thereafter; in addition, frequent sampling for HCV RNA and IFN 
kinetics was performed in-hospital during the first 4 days and between day 28–30. 
The genotype was assessed by a Line Probe Assay (Inno-LiPA, Innogenetics, Gent, 
Belgium). Quantification of plasma HCV RNA was performed at a single central 
laboratory by a rt-PCR assay with a sensitivity of 100 copies per milliliter (National 
Genetics Institute, Los Angeles, USA) (8). Liver biopsies were performed within 6 
months before retreatment and were reviewed by a central pathologist for presence or 
absence of cirrhosis. 
Non-response (NR) was defined as detectable HCV RNA at the end of therapy, 
response-relapse (RR) as HCV RNA undetectable at the end of therapy with re-
appearance during follow-up, and sustained response as undetectable HCV RNA at 
the end of therapy and after at least 24 weeks follow-up. 
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RESULTS 
 
The patient characteristics are summarized in table 1. In contrast to usual populations, 
a high percentage of cirrhosis was present in our study.  As all patients were originally 
selected based on absence of ALT normalisation during therapy, retrospective HCV 
RNA analysis showed that about 60% were virological non-responders, about 20% had 
a breakthrough and about 20% a virologic relapse during previous standard IFN 
monotherapy.  
 
 
Table 1 Baseline characteristics 
Characteristic Number/Total (%) 
Gender, male 11/22 (50%) 
Age, mean, years 46 
Genotype 1 15/22 (68%) 
Viral load > 2x 106 geq/ml 13/22 (59%) 
Cirrhosis 13/20 (65%) 
Virologic response to previous IFN therapy 
 NR (non-response)* 
 BT (breaktrough)a
 RR (response-relapse)b
 
13/22 (59%) 
5/22 (23%) 
4/22 (18%) 
 
* NR defined as persistently detectable HCV RNA at treatment weeks 4, 12 and 24, at the 
end of therapy and after 24 weeks of follow-up. 
a BT defined as temporary disappearance of detectable HCV RNA during treatment followed 
by re-appearance before the end of therapy and during follow-up. 
b RR defined as HCV RNA undetectable at the end of therapy and re-appearance during 
follow-up. 
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Table 2 Virologic response to treatment 
HCV RNA response 
to treatment 
Non-response* Response-relapsea Sustained 
responseb
Total population 15/22 (68%) 3/22 (14%) 4/22 (18%) 
By RNA response wk4c
 RNA negative 
 RNA positive 
 
- 
14/16 (88%) 
 
1/5 (20%) 
2/16 (12%) 
 
4/5 (80%) 
- 
By grade of fibrosis 
 Cirrhosis 
 No cirrhosis 
 
7/7 (100%) 
6/13 (46%) 
 
- 
3/13 (23%) 
 
- 
4/13 (31%) 
By genotype 
 Genotype 1 
 Genotype non-1 
 
12/15 (80%) 
3/7 (43%) 
 
1/15 (7%) 
2/7 (29%) 
 
2/15 (13%) 
2/7 (29%) 
By viral load (geq/ml) 
 High (>2x106) 
 Low (<2x106) 
 
4/9 (44%) 
11/13 (85%) 
 
3/9 (33%) 
- 
 
2/9 (22%) 
2/13 (15%) 
By gender 
 Male 
 Female 
 
8/11 (73%) 
7/11 (64%) 
 
1/11 (9%) 
2/11 (18%) 
 
2/11 (18%) 
2/11 (18%) 
By RNA response to 
previous IFN therapy 
 NR 
 BT 
 RR 
 
 
12/13 (92%) 
1/5 (20%) 
2/4 (50%) 
 
 
- 
2/5 (40%) 
1/4 (25%) 
 
 
1/13 (8%) 
2/5 (40%) 
1/4 (25%) 
 
* NR defined as detectable HCV RNA at the end of therapy and after 24 weeks of follow-up. 
aRR defined as HCV RNA undetectable at the end of therapy and re-appearance during 
follow-up. 
bSR defined as undetectable HCV RNA at the end of at least 24 weeks follow-up. 
c Response at week 4 unknown in 1 patient who eventually had a non-response. 
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The results are summarized in table 2. Eighteen percent had a sustained response, 
14% response-relapse and 68% non-response. Sustained responders were 
characterised by absence of cirrhosis, virological breakthrough or response-relapse on 
previous therapy and undetectable HCV RNA at week 4. Eight patients decided to 
withdraw from treatment because of lack of response at treatment week 4, and 8 
patients without a week 4 response continued; of the latter group, none reached a 
sustained response. 
Quantitative HCV RNA analysis of plasma samples showed that the mean drop in viral 
load was 2.5 log at day 3, and 2.6 log (99.7%) at week 2; at week 4 the average drop 
in viral load was 2.7 log. At week 4, all patients tested had at least a 1 log drop in viral 
load, 90% had a 2 log drop and 30% had a decrease of at least 3 log (figure 1). 
Common side effects were fatigue and depression, leading to treatment withdrawal in 
two patients (week 12 and 14). One patient developed hypothyroidism. One patient 
with compensated liver cirrhosis developed thrombocytopenia complicated by severe 
epistaxis; stopping treatment resulted in a prompt rise of the platelets. Leukopenia was 
observed in almost all patients, but did not lead to dose adjustments and was not 
associated with clinical significant infectious problems. No deaths were reported.
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Figure 1   
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DISCUSSION 
 
Retreatment of non-responders with standard doses IFN monotherapy did not lead to 
additional responses (9–11). For this reason, two treatment modalities for non-
responders were explored: combination of standard doses IFN with Ribavirin, and 
treatment with daily high doses IFN monotherapy. In our study, 18% of non-sustained 
responders to standard IFN monotherapy became sustained responder by daily high 
dose IFN. In patients with no HCV RNA response at all during previous treatment, 
sustained response was 8%; in those with a temporary response followed by a 
breakthrough or relapse, sustained response was 33%. In a meta-analysis of non-
responders to interferon, defined as lack of ALT normalisation during therapy, 
sustained response to retreatment with standard dose interferon was 2% (95% C.I. 
0–4%) versus 18% (14–23%) in retreatment with interferon ribavirin combination 
therapy (12). In our study in ALT non-responders, the sustained response rate was 
18% (5–40%), suggesting that daily high dose interferon retreatment might overcome 
part of the non-response to standard interferon therapy and approaches the efficacy 
of interferon ribavirin combination therapy in this difficult to treat patient group. In a 
meta-analysis of individual patient data of non-responders, defined as lack of RNA 
response to interferon therapy, retreatment with standard dose combination therapy 
led to a sustained response in 10% versus 23% in retreatment with high dose 
combination therapy (13), suggesting that dose increment of interferon might be 
useful in combination therapy as well. 
 
The RNA response patterns observed during high-dose treatment confirmed 
observations from the earlier Benelux study (14,15): 80% of patients with 
undetectable HCV RNA at week 4 (HCV <103 geq/ml) became sustained responder, 
in contrast to none of those with detectable RNA at week 4. Other predictors of 
response were the genotype, in accordance to the literature; another important pre-
treatment predictor seemed to be the presence or absence of cirrhosis. Again, this is 
in accordance with our earlier observations (3), whereas this factor is only of minor 
importance in combination therapy (16–18). 
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This pilot study confirms the concepts from Japanese studies, which document an 
important viral suppression by daily dosing of IFN (4). Measurement of viral load 
might distinguish between those with a drop in viral level and a chance of sustained 
response and those with a too low drop in viral levels to achieve a viral response by 
6-12 months. When validated techniques for measurement of quantitative HCV RNA 
became available, it was shown that, although HCV RNA became undetectable 
during treatment in only 32% of patients, all patients had a drop in the level of 
viraemia during the first 2 weeks with a mean decrease of 2.6 log (99.7%) (7).  
 
Thus, non-response does not appear to be equivalent to resistance to interferon; it 
may be the result of decreased sensitivity of HCV to interferon, of a low immune 
response, of altered pharmacokinetics, or of non-compliance. The resulting insights 
in viral behaviour during daily high dose interferon mono therapy formed the basis for 
a series of studies of these concepts in daily high dose combination therapy (19-22), 
aiming to improve the chances of cure for difficult to treat chronic hepatitis C. 
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ABSTRACT 
 
Background : Evidence based medicine depends on unbiased selection of 
completed randomized controlled trials. For completeness it is important to publish all 
trials. This report describes the first large randomised controlled trial where 
combination therapy was compared to placebo therapy and to ribavirin monotherapy, 
which has not been published untill now.  
 
Methods: One hundred and twenty one patients with chronic hepatitis C and 
elevated transaminases who did not respond to previous treatment with standard 
interferon monotherapy, were included from 16 centers in Belgium, the Netherlands 
and Luxembourg between 1992 and 1996. Patient poor-response characteristics 
were: genotype 1 (69%), HCV RNA above 2x106 copies/ml (55%) and cirrhosis 
(38%). Patients were randomized to 6 months combination therapy with interferon 
alpha-2b (3 MU tiw) and ribavirin (1000-1200 mg / day), 6 months ribavirin 
monotherapy (1000-1200 mg / day) or 6 months ribavirin placebo. The study was 
double blinded for the ribavririn / placebo component. One patient did not fit the entry 
criteria, and 3 did not start. All 117 patients who received at least one dose of 
treatment were included in the intention to treat analysis.  
 
Results: At the end of treatment, HCV RNA was undetectable in 35% of patients on 
combination therapy and in none of the patients treated with ribavirin monotherapy or 
placebo. The sustained virological response rate at 6 months after therapy was 15% 
for patients treated with interferon and ribavirin.  
During the 6 months treatment period 13% of patients on interferon ribavirin 
combination therapy, 13% of patients on ribavirin monotherapy and 11% of patients 
on placebo withdrew due to side effects or noncompliance.  At 24 weeks of treatment 
the mean Hb level was 85% of the baseline value, which means a mean decrease 
from 9.1 mmol/l to 7.8 mmol/l. The end of treatment Hb levels were not significantly 
different from patients treated with ribavirin monotherapy (p=0.76). End of treatment 
WBC was significantly lower in patients treated with combination therapy, compared 
to ribavirin (p<0.01) as well as for patients treated with ribavirin monotherapy 
compared to placebo (p<0.01).   
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Discussion: This belated report on the only placebo controlled study of interferon 
ribavirin combination therapy in non responders to standard doses of interferon 
monotherapy documents the effectiveness, be it limited, of this approach as well as 
the dynamics  of the effects on blood counts. 
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BACKGROUND 
 
Until a decade ago, interferon was the only drug available for the treatment of 
hepatitis C. Only a minority of patients had a sustained response to standard doses 
of interferon monotherapy. However, non-responders might be still amendable to 
therapy by either high-dose daily interferon (1) or by standard interferon in 
combination with ribavirin (2). This is a belated full report on the first and probably 
only RCT where combination therapy was assessed in comparison to ribavirin 
monotherapy and to placebo therapy. 
 
METHODS  
 
Participants 
Patients between 18 and 70 years of age with chronic hepatitis C, no ALT 
normalisation during and after treatment  and positive HCV RNA after treatment with 
interferon monotherapy, were elegible for the study. The previous treatment course 
consisted of three mega units interferon thrice weekly for 24 weeks or at least eight 
weeks of treatment with 6 mega units interferon thrice weekly or at least  4 weeks of 
10 mega units interferon thrice weekly. 
 
Patients with hepatitis of other viral origin, patients with inherited metabolic liver 
disease, patients with acquired metabolic liver disease related to alcohol, hepatotoxic 
drugs or obesity and patients with autoimmune hepatitis were excluded from the 
study. Other exclusion criteria were significant medical illness within the past five 
years, pregnancy or likelihood of becoming pregnant, immune modulating therapy 
(corticosteroids) within the past 6 months, inadequate levels of hemoglobin (<6 
mmol/l), platelet count (<50x10e9/l), white blood cells (<3x10e9/l), signs of 
hepatocellular carcinoma or decompensated liver disease, recent drug or alcohol 
addiction and unlikeliness to attend regularly for treatment and follow up. 
 
Data were collected in 16 centers in Belgium and in the Netherlands; central data 
collection was done in the Erasmus Medical Center in Rotterdam, the Netherlands. 
The study received ethics committee approval in all centers involved and all patients 
gave signed informed consent. 
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Interventions 
Patients were randomised and assigned to receive either ribavirin (ICN 
pharmaceuticals, Bucks, United Kingdom) monotherapy or a matched placebo orally 
twice a day in a total dose of 1200 mg a day (body weight ≥75 kg) or 1000 mg a day 
(body weight <75 kg) for 24 weeks, or interferon (Intron A, Schering Plough, 
Kenilworth, NJ, USA) 3 mega units thrice a week combined with ribavirin 1000 or 
1200 mg according to body weight during 24 weeks.  
 
All patients were assessed in an outpatient setting for safety, tolerance and efficacy 
at the end of weeks 2, 4, 8, 12, 16, 20 and 24 and every 4 weeks during follow up 
until week 48. Initial HCV-RNA was measured by bDNA with a lower detection limit of 
2000 copies/ml, HCV-RNA negativity at week 24 and week 48 was measured by 
PCR. HCV-RNA and hematologic- and biochemical parameters were measured in 
the certified laboraties of the participating hospitals; results were corrected for local 
normal values. Liver biopsies, taken withion 12 months before treatment were 
reviewed by the local pathologist for the presence or absence of cirrhosis.  
 
Objectives 
The objective of this study was to evaluate if interferon ribavirin combination therapy 
or ribavirin monotherapy would be a therapeutic option for non-responders to 
previous interferon therapy. 
 
Outcomes 
The primary endpoint for this study was defined as loss of detectable serum HCV 
RNA 24 weeks after the end of treatment. The secondary endpoint was normalisation 
of alanine aminotransferase 24 weeks after treatment.  
 
Sample size 
It was calculated that 120 patients (40 per treatment arm) were needed in order to 
have 90% chance of detecting a difference of 30% at the significance level of p=0.05 
(single sided testing) in disappearance of HCV RNA or normalization of ALT levels, 
assuming the frequency of these endpoints would be ten percent or less in the 
placebo group. 
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Criteria for 50% dose reduction of ribavirin were anemia with Hb <5.4 mmol/l or 
excessive subjective symptoms such as myalgia, fatigue or dyspepsia interfering 
severely with daily activities. Criteria for a 50% dose reduction of the total weekly 
interferon dose included leucopenia <1.5 x10e9/l, thrombocytopenia <40 x10e9/l or 
excessive subjective symptoms interfering with daily activities. 
 
Randomization 
Randomization was performed centrally at the coordination center in Rotterdam, the 
Netherlands after receiving all entry data, by opening an envelope (3). Patients were 
randomized to either combination therapy or monotherapy at a ratio of 1:2 after 
stratification for the presence of cirrhosis. The ribavirin and placebo arms were 
double blinded. Patients allocated to monotherapy received blinded study medication 
containing either ribavirin or placebo.  
 
Allocation concealment 
The randomization code of the monotherapy arms of the study remained concealed 
until all patients had completed their follow up and the database had been verified 
and closed. 
 
Statistical analysis 
All statistical analyses were performed using SPSS for Windows (Version 10 SPSS 
Inc, Chicago, IL, USA). The Kaplan Meier method was used to evaluate the time of 
ALT normalisation according to treatment using the log rank test to assess statistical 
significance. The Pearson Chi-square test was used to compare the differences in 
mean end of treatment and end of follow up response between the different groups. 
The Mann Whitney test was used to compare the differences in mean end of 
treatment blood counts.  
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RESULTS 
 
Participant flow 
121 patients were recruited from 16 university and affiliated hospitals in Belgium, the 
Netherlands and Luxembourg (‘Benelux’). Seventy seven patients had been treated 
in a previous Benelux study on interferon mono therapy (4), the other 44 had been 
treated with a comparable treatment schedule of 6 MU interferon thrice a week for at 
least 12 weeks or 3 MU for at least 24 weeks.  
 
One patient was excluded in view of a negative HCV RNA at baseline and three 
never started therapy.  All remaining 117 patients were included in the analysis (fig 
1). 
 
Recruitment 
Patients were recruited between 1992 and 1996.  
 
Baseline data 
There were no differences in patient characteristics between the 3 treatment groups 
(table 1). Patient poor-response characteristics were: genotype 1 (69%), HCV RNA 
above 2x106 copies/ml (55%) and cirrhosis (38%).  
 
Numbers analyzed 
The results are presented on the basis of patients who received at least one dosis of 
study medication, the intention to treat population. 40 patients received at least one 
dose of combination therapy, another 40 patients received at least one dose of 
ribavirin and 37 patients received at least one dose of placebo.  
 
Outcomes and estimation 
Patients who received combination therapy had significantly better responses than 
patients treated with ribavirin monotherapy or placebo, both virologically (HCV-RNA 
negativity) as well as biochemically (ALT normalisation) (fig 2). At the end of 
treatment, HCV RNA was undetectable in 35% of patients on combination therapy 
and in none of the patients treated with ribavirin monotherapy or placebo.  
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The sustained virological response rate at 6 months after therapy was 15% for 
patients treated with interferon and ribavirin (table 2).  
Eighteen percent of patients receiving combination therapy, 2.7% of patients 
receiving ribavirin monotherapy and 2.5% of patients receiving placebo treatment 
had persistently normal ALT levels during 24 weeks follow up (table 3).  
 
 
Table 1 Base-line characteristics of the patients (intention-to-treat population). 
 
Characteristic* Interferon and 
Ribavirin 6 mo 
(n=40) 
Ribavirin 6 
mo (n=40) 
Placebo 6 
mo (n=37) 
Age –  yr  47 ± 12 48 ± 12 46 ± 12 
Sex – M/F 28/12 28/12 31/6 
Serum ALT – times ULN 3.8 ± 2.0 3.8 ± 2.0 3.7 ± 1.6 
Serum HCV RNA†
   Copies/ml – log10 
   ≥2 x 106 copies/ml – % 
 
6.2 ± 0.8 
54 
 
6.3 ± 0.8 
55 
 
6.3 ± 0.7 
55 
Genotype – n (%) 
   1 
   2 or 3 
   other 
 
29 (79) 
6 (16) 
2 (5) 
 
24 (62) 
11 (22) 
4 (6) 
 
28 (76) 
8 (23) 
1 (3) 
Cirrhosis – n (%) 18 (45) 13 (33) 14 (38) 
 
*means ± SD. 
†Assessed by bDNA in 68 patients (24 interferon+ribavirin, 22 ribavirin, 22 placebo). 
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Figure 2 Cumulative probability of ALT response during treatment. 
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Intention to treat population, per treatment group. Response was defined as normal ALT on 
at least two sequential occasions, the time of response was taken at the first normal ALT. 
P=0,00 interferon + ribavirin vs placebo 
P=0,02 ribavirin vs placebo 
P=0,02 interferon + ribavirin vs ribavirin (Log rank test)
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Table 2 HCV RNA response at end of therapy and end of follow up, by therapy. 
HCV RNA negativity – n 
(%) 
Interferon and 
Ribavirin 6 mo  
(n=40) 
Ribavirin  
6 mo  
(n=40) 
Placebo  
6 mo  
(n=37) 
 
end of therapy 
 
14 (35) ¹ 
 
0 
 
0 
 
end of follow-up 
 
6 (15) ² 
 
0 
 
0 
 
¹ p<0.01 (Pearson Chi-square) 
² p<0.01 (Pearson Chi-square) 
 
 
Table 3 ALT response, by therapy group. 
ALT response – n (%) Interferon and 
Ribavirin (n=40) 
Ribavirin 
(n=40) 
Placebo  
 (n=37) 
 
On therapy¹  
 
End of treatment² 
 
End of follow up³ 
 
23 (58%) 
 
19 (48%) 
 
7 (18%) 
 
9 (23%) 
 
4 (10%) 
 
1 (2.7%) 
 
3 (8.1%) 
 
2 (5.4%) 
 
1 (2.5%) 
 
¹normal ALT on at least two occasions with at least 1 month interval, p<0.01 (Pearson 
Chi-square).  
²normal ALT at week 24 and at least one month earlier, p<0.01 (Pearson Chi-square). 
³persistently normal ALT levels during 24 weeks follow up, p=0.02 (Pearson Chi-square). 
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Adverse events 
Hemoglobin levels decreased in patients treated with combination therapy and in 
patients treated with ribavirin monotherapy (fig 3A). After week four a plateau-phase 
was reached.  There was a significant difference between the end of treatment Hb 
change of the patients receiving combination therapy or ribavirin monotherapy, 
compared to patients treated with placebo (p<0.01). The difference in mean end of 
treatment Hb change between combination therapy and ribavirin monotherapy was 
not statistically significant (p=0.76). 
 
Hemoglobin levels returned to baseline values for both groups within 8 weeks after 
cessation of treatment. Placebo treatment did not significantly affect hemoglobin 
levels. 
 
White blood counts decreased in patients treated with combination therapy with 
interferon and ribavirin (fig 3 B). At week 12 the mean WBC for this group was 64% 
from the baseline value.After week 12 a plateau-phase was reached. Ribavirin 
monotherapy also caused a progressive decrease in mean WBC.Placebo treatment 
did not affect WBC levels.  
 
The mean change in WBC at the end of treatment was greater for the patients 
treated with combination therapy than for patients treated with ribavirin monotherapy 
(p<0.01). There was also a significant difference between the end of treatment WBC 
change in patients receiving ribavirin monotherapy compared to patients treated with 
placebo (p<0.01).   
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Side effects 
During the 6 months treatment period 12.5% of patients on interferon ribavirin 
combination therapy, 12.5% of patients on ribavrin monotherapy and 10.8% of 
patients on placebo withdrew due to side effects or noncompliance (figure 1).  
 
In the group receiving combination treatment 3 patients needed dose reduction of 
interferon because of dyspnoea, depression and pyelonephritis One patient stopped 
interferon and had a dose reduction of ribavirin because of subjective side effects 
and anemia.  
 
Among patients treated with ribavirin, one had a dose reduction because of anemia 
which gave rise to cardiovascular complaints. One interrupted therapy because of 
vasculitis.  
 
Ancillary analyses 
Figure 4 shows the rates of ALT normalisation of 26 patients who were treated in a 
previous trial with interferon monotherapy (4) compared to the rates of ALT 
normalisation the same patients showed in this trial on combination therapy. There is 
a tendency towards increased ALT normalisation rate with interferon and ribavirin 
combination therapy.  
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Figure 4 Cumulative probability of ALT response during treatment. 
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Patients treated with combination therapy in this trial vs results of the same patients in a 
previous trial with interferon monotherapy (4). There is a trend towards increased 
normalisation rate with interferon and Ribavirin combination therapy. 
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DISCUSSION 
 
In 1992 there were two therapeutic options for patients not responding to standard 
doses of interferon monotherapy: treatment with high daily doses of interferon (1) or 
combination therapy with interferon and ribavirin.  
 
To test this second option we started this randomised controlled trial, in which we 
compared combination therapy with interferon and ribavirin to ribavirin monotherapy 
and to placebo. This trial is scientifically sound, with high enough numbers treated to 
draw reliable conclusions. The feasibility of such a trial was, however, low because of 
the placebo arm included; consequently it took several years for inclusion of all 
patients. 
 
Part of the results of this study were published in meta-analyses (5). This full report 
can still be of value for meta-analysis by the Cochrane approach and can serve as a 
reference for ribavirin monotherapy in non-responders and for placebo therapy in 
non-responders. 
 
This study documents a significant, though small effect of adding ribavirin to the 
treatment of non-responders. Since then various RCT have been published 
comparing combination therapy with interferon monotherapy (6–9). Saracco et al. 
reported sustained response rates comparable to the 15% we found in this study in 
patients assigned to a comparable treatment schedule (7). In meta-analyses that 
have been published on this subject, also response rates of 14–16% have been 
reported (10–13). One way to increase response rates in patients retreated with 
combination therapy, is to make a stricter selection and to treat only subgroups of 
patients who are more likely to have a sustained response. Camma et al state that 
sustained response rates can be increased to 30% by selecting patients less than 45 
years old with normal gammaglutamyltransferase levels and by treating them with 
high dose long course combination therapy (12). Indeed Saracco et al have shown 
that non-responders benefit the most from prolonged treatment with high dose 
interferon, achieving response rates up to 23 % in these patients.  
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In naive patients good results are obtained by treatment with pegylated interferon 
combined with ribavirin (14,15). New studies are on their way evaluating the effect of 
pegylated interferon and ribavirin in non-responders to interferon.  
 
This trial where combination treatment is compared to ribavirin monotherapy and 
placebo therapy, gives us the opportunity to determine which adverse effects can be 
expected from which medication. The decrease in WBC in combination therapy is 
mainly due to interferon, but also ribavirin causes a progressive and significant 
decrease in WBC.  
 
The decrease in Hb levels seen during combination therapy is almost entirely caused 
by ribavirin, with only a marginal additional effect of interferon.  
 
Conclusion: 
This belated report on the only placebo controlled study of interferon ribavirin 
combination therapy in non responders to standard doses of interferon monotherapy 
documents the effectiveness, be it limited, of this approach as well as the dynamics 
of the effects on blood counts. 
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Chapter 6 
ABSTRACT 
 
Background/Aims: There is consensus to stop interferon for hepatitis C if ALT 
remains elevated after 12 weeks; however, this may lead to unjust treatment 
withdrawal in ca 20% of potential sustained responders. No consensus exists for 
interferon-ribavirin combination therapy. The aim of this study was to assess the 
predictive value of an HCV RNA test at 4 weeks in comparison with ALT, both in 
interferon monotherapy and in interferon-ribavirin combination therapy. 
Methods: Plasma HCV RNA was tested at 4 weeks in 149 naive patients with 6 
months and 187 with up-to 12 months interferon monotherapy, and in 40 non-
responders treated with 6 months interferon-ribavirin combination. 
Results: For 6 and up to 12 months interferon monotherapy, the predictive value for 
non-response was 99% resp. 97% for a positive HCV RNA at week 4, versus 97% 
resp. 91% for an elevated ALT at week 12. Using a positive HCV RNA at week 4 as a 
stopping rule would lead to missing 5% resp. 12% of potential sustained responders, 
versus 10% resp. 28% for an elevated ALT at week 12. In interferon-ribavirin 
combination therapy, the predictive value for non-response was 100% for week 4 
HCV RNA versus 95% for week 12 ALT, and the potential sustained responders 
missed by a test was 0% for week 4 HCV RNA versus 20% for week 12 ALT. The 
overall sensitivity and specificity of a week 4 HCV RNA test was significantly better 
(area under ROC 0.85) as compared to testing ALT at either week 4 (0.78, p<0.001), 
week 8 (0.76, p<0.001) or week 12 (0.78, p<0.001). 
Conclusion: a positive HCV RNA test (≥103 copies/ml) at 4 weeks is highly 
predictive for non-response and leads to significantly less misidentification of 
potential sustained responders than ALT at week 4, 8 or 12, both in 6 or up to 12 
months interferon monotherapy and in 6 months interferon-ribavirin combination 
therapy of chronic hepatitis C. 
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INTRODUCTION 
 
For chronic hepatitis C the accepted duration of treatment with alpha interferon is - 
anno 1998 - 12 months (1,2), but treatment efficacy is still limited (3–5). To reduce 
the costs and prevent unnecessary treatment, it was recommended at consensus 
meetings in 1997 (1,2) to stop treatment if ALT levels did not normalize within 12 
weeks; the additional value of testing for HCV RNA was questioned (1,6). 
Recently, Tong et al. reported that measurement of HCV RNA at 12 weeks was more 
accurate than ALT in early identification of non-(sustained) responders to interferon 
therapy (7). In their study with 6 months interferon treatment (3 MU t.i.w.), an 
elevated ALT level at week 12 was 92% predictive for non-sustained response, but 
application of an elevated ALT at week 12 as a stopping rule would have led to 
missing 33% of the sustained responders. In contrast, a positive HCV RNA at week 
12 was 98% predictive for non-sustained response, and misidentified only 7% of the 
sustained responders. The question was raised whether testing for HCV RNA before 
week 12 might lead to even greater benefits and whether the results are also 
applicable to treatment for longer than 6 months and for the emerging new standard 
therapy of hepatitis C with interferon-ribavirin combination.  
In our centre we observed that plasma HCV RNA became undetectable already at 4 
weeks in sustained responders, and suggested a high predictive value of this time 
point (8). In an earlier paper on a large interferon monotherapy study in the Benelux, 
we already briefly mentioned the superior predictive value of this assessment 
compared to pretreatment factors like genotype, viral load and grade of fibrosis (9). In 
this paper, we extend this observation and report on the predictive value of HCV 
RNA testing at week 4 versus ALT at either week 4, 8 or 12, both for the large cohort 
of patients treated with interferon monotherapy (9) as well as for a cohort of patients 
treated within the Benelux with interferon-ribavirin combination therapy (10). 
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MATERIALS AND METHODS 
 
Patients 
For this study, data from patients, treated in two large randomized controlled trials 
performed in 19 hospitals in the Benelux were used. The first cohort was a group of 
336 naive chronic hepatitis C patients, with ALT levels at least twice the upper limit of 
normal, who were recruited between 1990 and 1993. One hundred and forty-nine 
patients were randomized to receive interferon monotherapy, 3 MU thrice a week 
(t.i.w.) for 6 months, and 187 patients received 6 MU interferon t.i.w. for 8 weeks, 
followed by dose reduction with a variable duration (dependent on response) with a 
maximum of 12 months (9). 
The second cohort was a group of 120 non-responders, recruited between 1992 and 
1996, characterized by presence of elevated ALT levels at the end of interferon 
monotherapy and elevated ALT levels and detectable plasma HCV RNA, 6 months 
after the end of treatment (10). These patients were randomized to receive placebo, 
6 months ribavirin monotherapy, or 6 months combination therapy of interferon 3 MU 
t.i.w. and ribavirin 1–1.2 g per day; only the latter group was included in the analysis 
(n=40). 
 
Assessment of ALT and HCV RNA 
ALT assessments were routinely performed every 4 weeks during treatment and 
every 4–6 weeks during the 6-month follow-up. ALT levels were determined at the 
participating trial centres and corrected for local normal values. Plasma samples for 
HCV RNA determination were routinely collected at start, week 4, end of treatment 
and end of follow-up. Samples for HCV RNA determination were processed within 2 
hours and stored at -70o C; all HCV RNA determinations were performed centrally at 
the coordinating centre in Rotterdam, using a validated in-house qualitative PCR 
assay with a sensitivity of ±103 copies per ml according to the Eurohep standard (11). 
 
Response criteria 
Sustained response (SR) was defined as undetectable HCV RNA at the end of the 6- 
month follow-up, together with persistently normal ALT levels during the 6-month 
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follow-up (measured on at least two occasions)1; all other patients were classified as 
non-sustained responders. The early biochemical and virological on-treatment 
responses were evaluated for their value to predict SR and non-SR. Biochemical on-
treatment response was assessed at weeks 4, 8 and 12 respectively and was 
defined as drop of the serum ALT level below the upper limit of normal. The 
virological on-treatment response was assessed at week 4 and was defined as 
plasma HCV RNA not detectable by the qualitative validated in-house assay. 
 
Statistical analysis 
For each test (ALT at week 4, 8 or 12, HCV RNA at week 4) we calculated its positive 
predictive value (chance of sustained response if the test is normal), its negative 
predictive value (chance of non-sustained response if the test is abnormal), its 
sensitivity (fraction of all sustained responders identified by a normal test) and its 
specificity (fraction of all non-responders identified by an abnormal test). Because of 
its clinical relevance, we also calculated the reverse forms of the sensitivity and 
specificity, i.e. the fraction of all (non-)sustained responders not identified by the test.  
For all tests the areas under the ROC curves were calculated and compared 
according to the method described by DeLong et al. (13). All calculations were made 
using SPSS software (SPSS Inc, Chicago, IL, USA) and Stata software (Stata Corp, 
Texas, TX, USA). 
 
                                                
1 In contrast to the definition proposed by Lindsay at the recent NIH consensus 
meeting (12), we did not include the criterion of repeatedly normal ALT’s at the end of 
treatment in this definition because of the observation that in 10–15% of proven long-
term (>5 years) sustained responders, ALT levels remained slightly elevated until the 
end of treatment. 
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RESULTS 
 
Interferon monotherapy 
Three hundred thirty-six naive HCV patients participated in a Benelux study on 
interferon monotherapy. The SR rate was 15% (95% confidence interval (CI) 11–
18%). 
In 280 patients a complete set of HCV RNA results at week 4 as well as ALT values 
at week 4, 8 and 12 was available. Table 1 displays the results of the analysis of this 
cohort according to treatment duration (6 months versus up-to 12 months). Using the 
outcomes of the ALT or HCV RNA tests as a stopping criterion early during 
treatment, the clinical most relevant goals are a high predictive value for non-
response and no exclusion of potential sustained responders. If HCV RNA was still 
detectable at week 4, the chance of non-SR was 99% and 97%, respectively, 
whereas it was 97% and 91%, respectively, in case of ALT normalization at week 12. 
If ALT normalization at week 12 had been used as stopping criterion, two out of 20 
(10%) sustained responders undergoing 6 months of treatment and seven out of 25 
(28%) sustained responders undergoing treatment for up to 12 months would have 
been missed, compared to only 5% and 12%, respectively, using HCV RNA 
assessment at week 4. Taking various combinations of ALT and HCV RNA criteria, 
e.g. HCV RNA response at week 4 with ALT normalization at week 12, did not lead to 
improvement of these results when compared to HCV RNA at week 4 alone (data not 
shown). In six out of the 45 (13%) proven long-term sustained responders, the ALT 
level even remained slightly elevated until the end of treatment. 
Out of the 336 naive patients treated with interferon monotherapy, 65% had  
genotype 1a or 1b infection. SR rates were 7% for genotype 1 versus 28% for the 
others. For genotype 1, the most relevant test characteristics were comparable for 
PCR at week 4 and ALT at week 12 (99% versus 98% prediction of non-response, 
14% versus 13% misidentification of response), while the overall test performance 
was better for HCV RNA at week 4 due to a better prediction of sustained response 
(20% versus 13%) and lower misidentification of non-response (27% versus 45%). 
For the other genotypes, HCV RNA at week 4 was superior over ALT assessment in 
all respects (Table 2). 
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Interferon-ribavirin combination therapy 
Forty non-responders to interferon monotherapy received 6 months treatment with 
combination of interferon and ribavirin; 80% had a genotype 1a or 1b. Five patients 
(12.5%, 95% C.I. 4–27%) had a sustained response. A complete set of ALT data at 
week 4, 8 and 12, together with HCV RNA results at week 4, was available for 31 
patients (including all five sustained responders). 
If week 4 HCV RNA remained detectable, the chance of non-SR was 100%, versus 
95% in case of ALT remained elevated at week 12 (Table 3); furthermore, one out of 
five (20%) SR would have been missed if ALT normalization at week 4, 8 or 12 had 
been used as criterion; in this patient, ALT remained elevated until the end of therapy 
and only normalized after treatment withdrawal. All five sustained responders were 
correctly identified by an undetectable HCV RNA at week 4. The odds ratios for ALT 
normalization as criterion did not reach statistical significance, whereas the odds for 
week 4 HCV RNA were infinite (95% CI 4.7–∞, p=0.0002). 
 
ROC curves 
Figure 1 shows the receiver operating characteristic (ROC) curves for HCV RNA 
testing at week 4 and ALT testing at week 4, 8 and 12 in the total group (125 patients 
with monotherapy for 6 months, 155 with monotherapy for up to 1 year, and 31 with 
interferon-ribavirin combination therapy). The area under the ROC curve was 
significantly higher for HCV RNA testing at week 4 (0.85) as compared to ALT testing 
at either week 4 (0.78, p<0.001), week 8 (0.76, p<0.001) or week 12 (0.78, p<0.001). 
The areas under the ROC curves were not significantly different between the ALT 
tests.  
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Figure 1 Value of testing ALT at week 4, 8 or 12 or HCV RNA at week 4 for early 
discrimination between eventual sustained responders and non-sustained 
responders. 
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The ROC curves show the relation per test between the chance of correctly identifying an 
eventual sustained responder versus the chance of giving a false positive result. An optimal 
test would approach 100% sensitivity at 0% false positivity, while a test without discriminative 
value would only reach 100% sensitivity at 100% false positivity. Differences between curves 
are evaluated by comparing the area under the ROC curves. The area under the ROC curve 
was significantly higher for testing HCV RNA at week 4 (0.85) as compared to ALT at either 
week 4 (0.78, p<0.001), week 8 (0.76, p<0.001) or week 12 (0.78. p<0.001), whereas no 
significant differences were observed between the ALT tests at week 4, 8 or 12. 
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DISCUSSION 
 
Treatment of chronic hepatitis C has been improved by prolonging treatment duration 
from 6 to at least 12 months (14) and by combining interferon with Ribavirin (15,16), 
but its efficacy is still limited. To reduce unnecessary exposure to treatment and its 
potential side-effects, and to reduce costs, guidelines have been sought to decide in 
an early stage whether continuation of treatment leads to a reasonable chance of 
success. Although pretreatment factors like viral load, genotype and grade of fibrosis 
can be used to predict the mean treatment outcome for study cohorts, they are of 
limited value in the individual patient (6,9). Based on observations in interferon 
monotherapy studies, it was proposed at the consensus conferences that – in 
addition to delineating a group with potential benefit of therapy – interferon treatment 
should be stopped if ALT values did not normalize within the first twelve weeks.  
This study shows that an HCV RNA test performed at 4 weeks of antiviral therapy 
has a high predictive value in identifying patients that have virtually no chance of 
reaching a sustained response with currently accepted treatment regimens; in 
addition, use of this test criterion affects the total number of sustained responders 
less than criteria based on ALT at 4, 8 or 12 weeks. 
Tong et al. (9) showed in his study with interferon monotherapy for 6 months that 
HCV RNA testing at week 12 had a high predictive value for non-response (98%) and 
only missed 1 out of 15 (7%) of the sustained responders. In our cohort with 6 
months interferon monotherapy, we found a similar high predictive value for non-
(sustained) response (99%, Table 1), with 5% misidentification of SR, when HCV 
RNA was assessed as early as 4 weeks after the start of therapy. Furthermore, a 
comparable efficacy of HCV RNA testing was observed in the cohort with variable 
treatment duration up-to one year. The latter is in accordance with the report of 
Gavier et al. on 181 patients treated with interferon monotherapy for 12 months (17), 
where it was observed that persistence of serum HCV RNA at 4 weeks of treatment 
predicted non-SR in 95% and missed only 8% of sustained responders versus 39% 
when ALT at week 12 had been used.   
The predictive value of an early ALT and HCV RNA assessment has not yet been 
reported for interferon-ribavirin combination therapy. Although limited in study size 
(n=40), our observation suggests that HCV RNA is at least as predictive as in 
interferon monotherapy, and its value in comparison with ALT is probably even larger 
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because ribavirin is known to lead to temporary ALT normalisations which are not 
accompanied by virus suppression or elimination. In addition, we made the same 
observation as in interferon monotherapy that in some of the proven long-term 
sustained responders ALT levels remain elevated until the end of therapy whereas 
HCV RNA was already undetectable at week 4 in all of them. This stresses the 
superiority of the HCV RNA detection over the ALT, which should not be used as a 
surrogate assay. 
Recently, Zeuzem et al. (18) argued that a quantitative evaluation of the initial 
response might be preferred over a qualitative test at week 4. Based on an assumed 
half-life of the virus, he calculated that all sustained responders should have at least 
3 log drop in viral load between start and week 4. Based on this assumption, he 
expected that sustained responders with a high pretreatment viral load (>2.106 
copies/ml) might still be HCV RNA positive at week 4 by qualitative PCR. However, 
15 of the 49 sustained responders in our group with interferon monotherapy had 
pretreatment viremia levels greater than 2.106 genome Eq/ml by bDNA, and all were 
HCV RNA negative at week 4 of therapy by qualitative PCR (sensitivity 103 
copies/ml). A so-called late response, i.e. PCR positive at week 4 and negative at 
end of treatment, followed by a sustained response, was observed in only 3 out of 
the 336 patients in our cohort treated with interferon monotherapy, and in none of the 
40 patients on interferon-ribavirin combination therapy. These observations are 
supported by the finding of Gavier et al. that the predictive value of the test is not 
improved when HCV RNA is assessed at week 12 in stead of week 4 (17). 
An objection to introducing our findings into clinical practice might be the variable cut-
off of the HCV RNA-PCR test (19). If the test is more sensitive than 103 copies per 
ml, as evolving technology is now producing, a qualitative test might lose its current 
predictive value; replacement with a quantitative test with a sensitivity below 103 
copies might then become the final answer. However, quantitative HCV RNA assays 
are at this moment poorly standardized, and either have limited sensitivity or lack 
linearity in the higher ranges (19,20). Thus, until the standardization issue is solved 
and performance of quantitative tests is established, a single qualitative HCV RNA 
assay at week 4 with a cut-off at 103 geneq/ml may be at least as predictive, easier in 
use, and more cost-effective than two quantitative assays. Another objective to 
implementation of a positive HCV RNA at 4 weeks as a stopping criterion might be 
that, although chances are very limited, a few potential responders might still be 
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missed. However, for these patients with chances of less than 5% of success if 
treatment is continued, it might be better to change to a more intense treatment 
modality like high-dose induction therapy which offers better chances of success in 
these specific cases (21,22). We suggest therefore that an HCV RNA test at 4 weeks 
is not used as a stopping rule, but as a management tool in deciding in whom to 
continue standard treatment and in whom to adjust it. Future research should explore 
whether this concept also holds for daily high-dose interferon therapy and for 
prolonged (≥1 year) interferon-ribavirin combination therapy. 
94 
early prediction of response in HCV 
ACKNOWLEDGMENTS 
 
The authors are grateful to the participants in the Benelux Study Group on Treatment 
of Chronic Hepatitis C who contributed to the database which was used for this 
report: M. Adler1, V. Arendt2, N. Bourgeois1, J. Belaiche3, R. Brénard4, C.M. 
Bronkhorst5, J.T. Brouwer6, P. Buydens7, R.A.F.M. Chamuleau5, J. Delwaide3, 
Th.J.M. van Ditzhuysen8, L.J. van Doorn9, A. Elewaut10, A.E. Elewaut10, H. Fierens11, 
J. Fevery12, C. de Galocsy13, A.P. Geubel4, J de Groote12, B.E. Hansen6, J. van 
Hattum14, M.L. Hautekeete7, R.A. Heijtink6, J. Henrion15, B. van Hoek16, W.C.J. Hop6, 
P.L.M. Janssen5, F.J.W. ten Kate5, G.E.M. Kleter6, G. Leroux-Roels10, P. 
Michielsen11, J.P. van Munster17, F. Nevens12, H.G.M. Niesters6, J.W. den Ouden18, 
D. Overbosch19, J. Pirotte3, M. Rasch14, H.A.R.E. Tuynman20, W.G.V. Quint9, H.W. 
Reesink5, S.W. Schalm6, van Steenbergen12, J. Versieck10, R.A. de Vries21, J. 
Weber2, P.J. Wismans22, S.H. Yap12. 
 
1Erasme University Hospital Brussels, Belgium; 2Centre Hospitalier de Luxembourg, 
Luxembourg; 3University Hospital Liège, Belgium; 4St Joseph Hospital, Gilly and University 
Hospital St Luc, Brussels, Belgium; 5Academic Medical Centre Amsterdam, the Netherlands; 
6Dijkzigt University Hospital and Erasmus University Rotterdam, the Netherlands; 7Free 
University Hospital Brussels, Belgium; 8Willem Alexander Hospital, 's Hertogenbosch, the 
Netherlands; 9Diagnostic Centre SSDZ, Delft, the Netherlands; 10University Hospital Gent, 
Belgium; 11University Hospital Antwerpen, Belgium; 12Gasthuisberg University Hospital 
Leuven, Belgium; 13St Anne Hospital, Brussels, Belgium; 14University Hospital Utrecht, the 
Netherlands; 15Jolimont Hospital, Haine St Paul, Belgium; 16University Hospital Leiden, the 
Netherlands; 17University Hospital St Radboud, Nijmegen, the Netherlands; 18St Franciscus 
Hospital, Rotterdam, the Netherlands; 19Rode Kruis Hospital, the Hague, the Netherlands; 
20Medical Centre Alkmaar, the Netherlands; 21Rijnstate Hospital Arnhem, the Netherlands; 
22Haven Hospital, Rotterdam, the Netherlands. 
 
The authors thank G.R. Jhinkoe Rai for assistance in the data collection and S.N. de 
Vlaming for assistance in preparation of the manuscript. 
95 
Chapter 6 
REFERENCES 
 
1. Anonymous. National Institutes of Health Consensus Development conference Panel 
statement: management of hepatitis C. Hepatology 1997;26:2S-10S. 
2. Dhumeaux D, Doffoel M, Galmiche JP. A French consensus conference on hepatitis 
C: screening and treatment. J Hepatol 1997;27:941-4. 
3. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, et al. 
Randomized trial comparing three different regimens of alpha-2a-interferon in chronic 
hepatitis C. The TriVeneto Viral Hepatitis Group. Hepatology 1995;22:700-6. 
4. Lin R, Roach E, Zimmerman M, Strasser S, Farrell GC. Interferon alfa-2b for chronic 
hepatitis C: effects of dose increment and duration of treatment on response rates. 
Results of the first multicentre Australian trial. Australia Hepatitis C Study Group. J 
Hepatol 1995;23:487-96. 
5. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, et al. A 
comparison of three interferon alfa-2b regimens for the long- term treatment of 
chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 
1995;332:1457-62. 
6. Davis GL, Lau JY. Factors predictive of a beneficial response to therapy of hepatitis 
C. Hepatology 1997;26:122S-7S. 
7. Tong MJ, Blatt LM, McHutchison JG, Co RL, Conrad A. Prediction of response during 
interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical 
characteristics: a comparison. Hepatology 1997;26:1640-5. 
8. Kleter GE, Brouwer JT, Heijtink RA, Schalm SW, Quint WG. Detection of hepatitis C 
virus RNA in patients with chronic hepatitis C virus infections during and after therapy 
with alpha interferon. Antimicrob Agents Chemother 1993;37:595-7. 
9. Brouwer JT, Nevens F, Kleter B, Elewaut A, Adler M, Brenard R, et al. Efficacy of 
interferon dose and prediction of response in chronic hepatitis C: Benelux study in 
336 patients. J Hepatol 1998;28:951-9. 
10. Brouwer JT, Nevens F, Michielsen P, Hautekeete ML, Chamuleau RAFM, Adler M, et 
al. What options are left when hepatitis C does not respond to interferon? Placebo 
controlled Benelux multicentre retreatment trial on ribavirin monotherapy versus 
combination with interferon. J Hepatol 1994;21 (suppl 1):S17 Abstract. 
11. Kleter GE, van Doorn LJ, Brouwer JT, Schalm SW, Heijtink RA, Quint WG. Sequence 
analysis of the 5' untranslated region in isolates of at least four genotypes of hepatitis 
C virus in The Netherlands. J Clin Microbiol 1994;32:306-10. 
12. Lindsay KL. Therapy of hepatitis C: overview. Hepatology 1997;26:71S-7S. 
13. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or 
more correlated receiver operating characteristic curves: a nonparametric approach. 
Biometrics 1988;44:837-45. 
14. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-
analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of 
dose and duration. Hepatology 1996;24:778-89. 
15. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, et al. 
Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic 
hepatitis C. Meta-analysis of individual patient data from European centres. J Hepatol 
1997;26:961-6. 
16. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. 
Randomised, double-blind, placebo-controlled trial of interferon alpha- 2b with and 
without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 
1998;351:83-7. 
17. Gavier B, Martinez-Gonzalez MA, Riezu-Boj JI, Lasarte JJ, Garcia N, Civeira MP, et 
al. Viremia after one month of interferon therapy predicts treatment outcome in 
patients with chronic hepatitis C. Gastroenterology 1997;113:1647-53. 
18. Zeuzem S, Lee JH, Franke A, Ruster B, Prummer O, Herrmann G, et al. 
96 
early prediction of response in HCV 
Quantification of the initial decline of serum hepatitis C virus RNA and response to 
interferon alfa. Hepatology 1998;27:1149-56. 
19. Pawlotsky JM. Measuring hepatitis C viremia in clinical samples: can we trust the 
assays? Hepatology 1997;26:1-4. 
20. Damen M, Cuypers HT, Zaaijer HL, et al. International collaborative study on the 
second EUROHEP HCV-RNA reference panel. J Virol Methods 1996;58:175-85. 
21. Iino S, Hino K, Kuroki T, Suzuki H, Yamamoto S. Treatment of chronic hepatitis C 
with high-dose interferon alpha-2b. A multicenter study. Dig Dis Sci 1993;38:612-8. 
22. Bekkering FC, Brouwer JT, Leroux-Roels G, Vlierberghe H van, Elewaut A, Schalm 
SW. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-
responders to standard therapy. J Hepatol 1998;28:960-4 
 
97 
  
 Chapter 7 
 
 
 
Reduction of relapse rates by 18-month 
treatment in chronic hepatitis C. A Benelux 
randomized trial in 300 patients 
 
 
Johannes T. Brouwer1*, Frederik Nevens2, Frank C. Bekkering1, 
Nadine Bourgeois3, Hans Van Vlierberghe4, Christine J. 
Weegink5, Véronique Lefebvre6, Jan van Hattum7, Jean 
Henrion8, Jean Delwaide9, Bettina E. Hansen10 and Solko W. 
Schalm1, for the Benelux Study Group on Treatment of Chronic 
Hepatitis C 
 
Departments of Hepatogastroenterology of the 1Erasmus Medical Center Rotterdam, 
The Netherlands, 2University Hospital Leuven, Belgium, 3Erasme University Hospital 
Brussels, Belgium, 4University Hospital Gent, Belgium, 5Academic Medical Center 
Amsterdam, The Netherlands, 6Centre Hôpital Régionale St. Camille Namen, 
Belgium, 7University Hospital Utrecht, The Netherlands, 8Jolimont Hospital Haine St 
Paul, Belgium and the 9University Hospital Liège, Belgium 
10Department of Biostatistics, Erasmus University, Rotterdam, the Netherlands 
*Current address first author: the Reinier de Graaf Hospital Group, Delft, the 
Netherlands 
 
Journal of Hepatology 2004; 40: 689–695 
 
Chapter 7 
ABSTRACT 
 
Background /Aims Treatment of chronic hepatitis C with Interferon can be 
ineffective due to relapse. We aimed to reduce the 40% relapse rate of 6 months 
interferon–ribavirin combination therapy by prolonging treatment to 18 months. 
Methods Three hundred patients with treatment-naive hepatitis C, were 
randomized to 18 months combination therapy with Interferon (3 MU tiw) and 
Ribavirin (1000–1200 mg/day), 18 months Interferon combined with placebo, or 6 
months combination therapy with Interferon and Ribavirin, in a double blinded 
manner. All 295 patients who received at least one dose of treatment were included 
in the intention to treat analysis. 
Results At the end of treatment, HCV RNA was undetectable in 55 and 49% of 
those on 6 and 18 months combination therapy, respectively, versus 26% of those on 
monotherapy (p<0.001). The relapse rate was 38% for 6 months combination 
therapy, 38%  for 18 months monotherapy, and only 13% for 18 months combination 
treatment (p=0.002). The sustained response rates were 34% for 6 months 
combination therapy, 16% for 18 months monotherapy and 43% for 18 months 
combination therapy (p<0.05). 
Interpretation Reduction of relapse rates to 15 percent or less is feasible by 
prolongation of interferon–ribavirin treatment to 18 months. 
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INTRODUCTION 
 
Sustained virological response to treatment of chronic viral hepatitis C (HCV) is 
hampered predominantly by two biological phenomena: incomplete efficacy of 
interferon (IFN) in blocking viral replication, resulting in an initial virological non-
response, and incomplete immune-mediated removal leading to relapse after 
treatment withdrawal (1–3). The introduction of Pegylated-interferon (PEG-IFN) has 
reduced the initial virological non-response significantly, but did not affect relapse 
rates (4–7). Ribavirin leads to both an enhanced initial response and a reduction of 
relapse, especially in genotype 2 and 3 patients (8–10). However, relapse rates 
remain 30 to 40% in genotype 1, even with optimal dosed PEG-IFN and Ribavirin 
combination therapy (11–13). Relapse is also significantly related to duration of 
treatment (14). The first indications that relapse rates could be reduced by prolonging 
therapy beyond 12 months came from IFN mono-therapy studies (15,16). The 
Benelux study presented here aimed at reducing the relapse rate in IFN-Ribavirin 
combination therapy by prolonging the treatment duration from 6 months (the 
expected standard at the time of the design) to 18 months. To assess whether a 
comparable reduction of relapse could be achieved by prolonged IFN monotherapy, 
the 6 months combination therapy was compared not only to 18 months combination 
therapy, but also to 18 months of IFN mono-therapy.  
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MATERIALS AND METHODS 
 
Patients 
Patients aged 18 years or older were eligible if they had biopsy documented chronic 
hepatitis C (anti-HCV antibodies, detectable HCV RNA, compatible liver biopsy in the 
past 12 months) and elevated serum ALT levels on at least 2 occasions within the 2 
months prior to study entry. Patients were excluded if they had had previous antiviral 
treatment, decompensated liver disease, co-infection with HBV or HIV, other causes 
of liver disease, cytopenia (Hb below lower limit of normal, platelet count <100x109/l, 
granulocyte count <1.5x109/l), substance abuse or any other significant medical 
illness that might interfere with the trial.  
The study was initiated in 25 centers in Belgium, the Netherlands and Luxembourg. 
The study was approved by the institutional review board of each participating center 
and written informed consent was obtained from each patient before entry. 
 
Study design 
The sample size was based on an estimated sustained response rate of 65% for 
long-term combination therapy, 40% for short-term combination therapy and 25% for 
long-term monotherapy. It was calculated that 83 patients per group were needed in 
order to have a power of 80 percent to detect a difference of 25 percent in sustained 
response rate between long-term combination therapy and the other two groups at a 
2.5 percent level of significance (two two-sided tests with Bonferroni correction for 
multiple testing). To account for a potential dropout rate of about 10%, the study size 
was set to 300 patients. 
Patients who met the inclusion criteria were randomly assigned to one of the three 
treatment arms in a ratio of 1:1:1 with stratification for center and presence or 
absence of cirrhosis. Treatment arms consisted of Interferon alpha-2b (Intron-A, 
Schering-Plough, Kenilworth, NJ, USA) 3 million units thrice weekly combined with 
ribavirin (Rebetol, Schering-Plough) 1200 mg/day (1000 mg if bodyweight < 75 kg) 
for either 6 months (short-term combination therapy) or 18 months (long-term 
combination therapy), or in combination with placebo for 18 months (long-term 
monotherapy). The study was performed double-blinded. At randomization the 
patient received a trial-number, which corresponded to blinded study medication 
containing either Ribavirin or placebo and to a closed envelop at the coordination 
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center with information on allocated treatment duration. At 6 months the envelop was 
opened and the treating physician was informed whether the patient had to stop. 
Patients were allowed to discontinue therapy at month 6 if HCV RNA remained 
detectable with ALT levels at least 1.5 times the upper limit of normal. Criteria for 
50% dose reduction were Hb <10 g/dl or <6.2 mmol/l (ribavirin), WBC <1.5x109/l 
(IFN), platelets <50x109/l (IFN) or intolerable side effects.  
The randomization code of the study remained concealed until all patients had 
completed their follow-up and the database had been verified and closed. 
 
Assessments and study end points 
Patients were seen at treatment week 2 and 4, every month till month 6 and every 3 
months thereafter; follow-up visits were at 3 and 6 months after the end of therapy. 
The efficacy end-points were virological response, defined as undetectable HCV 
RNA at the end of treatment and the end of 6 months follow-up. HCV RNA was 
measured at a single central laboratory by rt-PCR assay with a sensitivity of 100 
copies per milliliter (National Genetics Institute, Los Angeles, USA) (17). The HCV 
genotype was determined with the INNO-LiPA HCV second generation assay 
(Innogenetics, Zwijnaarde, Belgium). Hematologic and biochemical tests were 
performed in the certified laboratories of the participating hospitals; results were 
corrected for local normal values. Liver biopsies, taken within 12 months before 
treatment, were reviewed by the local pathologists for the presence or absence of 
cirrhosis. 
All patients who were randomized and who received at least one dose of study 
medication were included in the intention to treat analysis. Patients with missing 
follow-up data were classified as remaining HCV RNA positive. In addition, a per 
protocol analysis was performed including all evaluable patients who completed their 
treatment and follow-up or who had dose reduction or discontinued prematurely 
according to the criteria of the protocol. 
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Statistical analysis 
The baseline characteristics of the treatment groups were compared with use of the 
chi-square test or the Wilcoxon rank-sum test. The treatment responses were 
compared with use of the chi-square test or the Fisher’s exact test where 
appropriate. The relapse rate was calculated by the fraction of individuals with 
undetectable HCV RNA at the end of treatment who had detectable HCV RNA after 6 
months follow-up. The relation between pretreatment variables and response or 
relapse was examined by backwards stepwise logistic regression. The analysis was 
performed using SPSS v. 10 software (SPSS Inc, Chicago, IL, USA). 
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RESULTS 
 
Between March 1996 and April 1997, 300 patients were enrolled in the study. Of 
those, 295 patients received at least one dose of study medication and were included 
in the intention to treat analysis. The groups were well balanced (Table 1). With 
regard to poor-response characteristics, 71% had a genotype 1 infection, 61% had a 
viral load ≥ 2x106 copies/ml and 14% had liver cirrhosis.  
During the first 6 months, 11% of patients on combination therapy and 6% of those 
on interferon monotherapy discontinued treatment because of adverse events or 
noncompliance (Figure 1) (n.s.). Seventy-two out of 97 patients on 18 months 
combination therapy (74%), 77 patients out of 101 on 18 months monotherapy (76%) 
and 85 patients out of 97 on 6 months combination therapy (88%) completed 
treatment and follow-up, had dose reduction or withdrew from treatment in 
accordance with the protocol and were included in the per protocol analysis (n=234). 
 
Table 1 Base-line characteristics of the patients (intention-to-treat cohort) 
Characteristica Interferon 
and Ribavirin 
6 months 
(n=97) 
Interferon 
and Ribavirin 
18 months 
(n=97) 
Interferon 
and placebo 
18 months 
(n=101) 
Age (yr)  43 ± 12 47 ± 14 45 ± 14 
Sex (M/F) 43/54 61/36 64/37 
Weight (kg) 73.0 ± 16 74.2 ± 14 74.5 ± 13 
Serum ALT – times ULN 2.9 ± 2.1 3.1 ± 1.9 3.6 ± 2.7 
Serum HCV RNA 
   copies/ml – log10 
   ≥2 x 106 copies/ml – % 
 
6.3 ± 0.7 
54 
 
6.4 ± 0.7 
68 
 
6.3 ± 0.8 
61 
Genotype – n (%) 
   1 
   2 or 3 
   other 
 
73 (75) 
18 (19) 
6 (6) 
 
68 (70) 
22 (23) 
7 (7) 
 
68 (67) 
23 (23) 
10 (10) 
Cirrhosis – n (%) 12 (12) 15 (16) 14 (14) 
 
a Plus–minus values are means ± SD. 
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Figure 1 Trial profile 
300 patients randomized   
100 allocated to interferon
+ ribavirin 18 months
101 allocated to interferon
+ placebo 18 months
99 allocated to interferon
+ ribavirin 6 months
2 received 
no treatment
3 received 
no treatment
97 received treatment      101 received treatment     97 received treatment     
•6 patients discontinued
treatment between week
0 and 28 (1 per protocol)
•27 patients stopped
treatment at week 28
for nonresponse
(HCV RNA + and ALT
>1.5 ULN at week 24)
(24 per protocol)
•19 patients discontinued
treatment between week
28 and 76 (3 per protocol)
•11 patients discontinued
treatment between week
0 and 28 (3 per protocol)
•9 patients stopped
treatment at week 28
for nonresponse
(HCV RNA + and ALT
>1.5 ULN at week 24)
(7 per protocol)
•15 patients discontinued
treatment between week
28 and 76 (2 per protocol)
•10 patients discontinued
treatment between week
0 and 28 (1 per protocol)
62 patients completed 76 wks 
74 patients treated per protocol
87 patients completed 28 wks 
88 patients treated per protocol
49 patients completed 76 wks 
77 patients treated per protocol
3 patients not evaluable
for follow-up
2 patients not evaluable
for follow-up
0 patients not evaluable
for follow-up
85 patients had treatment
and follow-up according
to the protocol
72 patients had treatment
and follow-up according
to the protocol
77 patients had treatment
and follow-up according
to the protocol
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Virologic responses 
More than 80% of the virologic responses on combination therapy and 70% of those 
on monotherapy occurred within the first 3 months of treatment (Fig. 2). Almost no 
increase in HCV RNA response was observed in prolonged combination therapy 
after month 6.  
A breakthrough with recurrence of detectable HCV RNA before the end of treatment 
occurred in 8% of patients on combination therapy and 24% of those on IFN 
monotherapy (p=0.015). At the end of treatment, HCV RNA was undetectable in 49% 
(95% C.I. 39–60%) of patients on long-term combination therapy, 55% (45–65%) of 
those on short-term combination therapy and 26% (18–35%) of those on long-term 
monotherapy (p<0.001). 
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The HCV RNA relapse rate after 18 months combination therapy was 13% (5–25%), 
compared to 38% (20–59%) with 6 months combination therapy (p=0.006) and 38% 
(25–52%) with 18 months monotherapy (p=0.017) (Table 2).  
 
 
 
 
Table 2 Relation of baseline characteristics to HCV RNA relapse during follow-
up in the 127 patients who had a HCV RNA response at the end of treatment 
Characteristica Interferon 
and ribavirin 
6 months 
(n=53) 
Interferon 
and ribavirin 
18 months 
(n=48) 
Interferon 
and placebo 
18 months 
(n=26) 
Total HCV RNA relapse (%) 
 Intention to treat 
 Per protocold
 
20/53 (38)
20/50 (40) 
 
6/48 (13)b,c 
3/39 (8) b,c
 
10/26 (38)
6/19 (32) 
Cirrhosis 
 N 
 Y 
 
17/49 (35)
3/4 
 
6/40 (15) b,c 
0/8 b,c
 
8/22 (36)
2/4 
Serum HCV RNA 
 <2 x 106 copies/ml 
 ≥2 x 106 copies/ml 
 
7/28 (25) 
13/23 (57) 
 
2/17 (12) 
4/29 (14) b,c
 
1/10 (10) 
8/14 (57) 
Genotype  
 1 Intention to treat 
     Per protocold 
 2 or 3 
 other 
 
16/34 (47)
16/32 (50) 
3/16 (19) 
1/3 
 
4/29 (14) b,c 
1/25 (4)b 
2/16 (13) 
0/3 
 
6/15 (40)
2/10 (20) 
4/10 (40) 
0/1 
 
a Intention to treat analysis was used in all cases unless stated otherwise 
b Significant difference between 18 months IFN + ribavirin and 6 months IFN + ribavirin 
(p<0.05) 
c Significant difference between 18 months IFN + ribavirin and 18 months IFN + placebo 
(p<0.05)  
d Treated, had dose reduction or stopped earlier, according to the criteria of the protocol 
(included dose reduction or stopping earlier because of nonresponse or persisting side-
effects despite dose reduction; excluded non-compliance, protocol violations, non-
classifiable because of incomplete follow-up) 
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A sustained HCV RNA response was achieved in 43% (33-53%) of patients on long-
term combination therapy, 34% (24-44%) of those on short-term combination therapy 
and only 16% (9-23%) of those on long-term monotherapy (p<0.001) (Table 3).  
 
 
 
 
 
Table 3 Relation of baseline characteristics to sustained HCV RNA response  
 
Characteristica Interferon 
and ribavirin 
6 months 
(n=97) 
Interferon 
and ribavirin 
18 months 
(n=97) 
Interferon 
and placebo 
18 months 
(n=101) 
Total sustained response (%) 
 Intention to treat 
 Per protocolc
 
33/97 (34)
30/85 (35) 
 
42/97 (43)b 
36/72 (50)b,d
 
16/101 (16)
13/77 (17) 
Cirrhosis 
 N 
 Y 
 
32/85 (38)
1/12 (8) 
 
34/82 (41)b 
8/15 (53)b,d
 
14/86 (16)
2/14 (14) 
Serum HCV RNA 
 <2 x 106 copies/ml 
 ≥2 x 106 copies/ml 
 
21/42 (50)
10/50 (20) 
 
15/30 (50)b 
25/63 (40)b,d
 
9/37 (24)
6/58 (10) 
Genotype  
 1 Intention to treat 
     Per protocolc
 2 or 3 
 other 
 
18/73 (25)
16/63 (25) 
13/18 (72)
2/6 
 
25/68 (37)b 
24/55 (44)b,d 
14/22 (64)b 
3/7 
 
9/68 (13)
8/50 (16) 
6/23 (26)
1/10 (10) 
 
a Intention to treat analysis was used in all cases unless stated otherwise 
b Significant difference between 18 mo IFN + Ribavirin and 18 mo IFN + placebo (p<0.05) 
c Treated, had dose reduction or stopped earlier, according to the criteria of the protocol 
d Significant difference between 18 mo IFN + Ribavirin and 6 mo IFN + Ribavirin (p<0.05)
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Factors associated with relapse and sustained response 
Table 2 shows the relation of baseline characteristics to HCV RNA relapse in the 127 
patients who had a response at the end of treatment. Eighteen months combination 
therapy led to a significant reduction of relapse in all poor response categories 
(cirrhosis, high viral load, genotype 1). In fact, the relapse rates after 18 months 
combination therapy approached those of the favorable categories (no cirrhosis, low 
viral load, genotype 2 or 3). This effect was visible both in early responders, who got 
undetectable HCV RNA within the first 3 months of treatment, and late responders. 
Relapse rates in early responders were 8% (2–21%) with 18 months combination 
therapy versus 30% (17–46%) in 6 months combination treatment and 28% (10–
53%) in 18 months monotherapy (p=0.03). In late responders, relapse rates were 
30% (7–65%) with 18 months combination therapy versus 70% (35–93%) with 6 
months combination therapy and 63% (24–91%) with 18 months IFN monotherapy 
(p=0.2). Factors associated with sustained response (SR) in the univariate analysis 
are shown in Table 3. 
  
In the multivariate analysis, the only significant factor which influenced the response 
for genotypes 2 and 3 was the additional use of ribavirin: IFN monotherapy led to a 
significant lower on-treatment response (odds ratio 0.1, 95% C.I. 0.02–0.5, p=0.007) 
and sustained response (OR 0.1, C.I. 0.02–0.5, p=0.004) compared to combination 
therapy. Neither any of the pretreatment factors (gender, cirrhosis, viral load) nor the 
prolongation of combination treatment from 6 to 18 months significantly affected the 
response and relapse rate in genotype 2 or 3.  
For genotype 1, factors which had an independent effect on the response and 
relapse rates were the type of treatment and the pre-treatment viral load. 
Prolongation of treatment from 6 to 18 months significantly reduced the chance of 
relapse, both after IFN monotherapy (OR 0.03, C.I. 0.002–0.6, p=0.02) and after IFN-
Ribavirin combination therapy (OR 0.01, 95% C.I. 0.001–0.1, p<0.001). The resulting 
sustained response rate for 18 months IFN monotherapy did not differ significantly 
from that of 6 months combination therapy. In contrast, 18 months combination 
therapy in genotype 1 patients led to a significantly increased chance of sustained 
response, both in comparison to 18 months IFN monotherapy (OR 6, C.I. 2–19, 
p=0.001) and in comparison to 6 months combination treatment (OR 4, C.I. 2–10, 
p=0.004).  
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Patients with genotype 1 and a high viral load (≥2 x106 copies/ml) had, compared to 
those with a low viral load, a reduced chance of response during treatment (OR 0.4, 
C.I. 0.2–0.9, p=0.02), a markedly increased risk for relapse (OR 18, C.I. 3–121, 
p=0.03) and a significantly reduced chance for sustained response (OR 0.2, C.I. 
0.09–0.5, p<0.01). 
 
Adverse events 
Ten percent of patients in the group with 6 months combination therapy, 25% of 
those with 18 months combination therapy and 25% of those with 18 months IFN 
monotherapy discontinued their treatment prematurely because of adverse events or 
because of noncompliance (Figure 1). The profile of adverse events for monotherapy 
and combination therapy was comparable to that of previous reports (9,10) (data not 
shown). Adverse events leading to treatment withdrawal and/or hospitalisation 
occurred in six cases with 6 months combination therapy, in 15 cases with 18 months 
combination therapy (eight before month 6, four between month 6 and 12, two after 
month 12 and one in the follow-up period) and in six cases with 18 months 
monotherapy (four before month 6, one between month 6 and 12, and one 
thereafter). 
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DISCUSSION 
 
Treatment results in chronic hepatitis C have considerably improved over the last 
decennium, but the efficacy of therapy is still limited for the most common genotype 1 
due to a low response rate during therapy and a high relapse rate after therapy.  
Efforts have been made to improve the initial response rate by giving higher and daily 
IFN dosages as induction treatment (18,19). Although induction leads to a higher 
initial response, this effect is often lost after dose reduction (20–23). Prolonged 
induction treatment is still under consideration (24,25). 
The documentation that relapse could be reduced by prolongation of treatment came 
from the early HCV studies, which were assessed by the ALT response (26). The 
studies of Poynard et al. (15) and Lin et al. (16) showed a reduction of ALT relapse 
from around 70% with 6 months IFN monotherapy to 50% with 18 months treatment, 
respectively, 46% with 24 months therapy. The marked effect of combining interferon 
with ribavirin with reduction of relapse rates by 50% or more (8–10,27) appeared to 
negate the need for therapy beyond 12 months.  
Recent experiences with PegInterferon (PEG-IFN) and ribavirin have shown (11–13) 
that such treatment of patients with genotype 2 or 3 is associated with cure rates 
over 80 percent. However, even with 12 months of PEG-IFN plus ribavirin, sustained 
response rates in genotype 1 remain less than 50% which in part is due to the fact 
that the relapse rates remain 30 percent or higher (11). PEG-IFN leads to a higher 
initial response but not to reduction of relapse rates (4–7). The Benelux study 
presented here shows that by prolonging the duration of IFN–ribavirin combination 
therapy to 18 months the relapse rate in genotype 1 patients could be reduced to 
less than 14%, which is comparable to current treatment results in genotype 2/3 
patients. 
How valid are these results? The patient population included is large enough to 
prevent bias by small numbers. The patients were recruited from 25 major hospitals 
in 3 countries, and no special selection process was used. In fact, poor response 
criteria like cirrhosis and genotype 1 were more prevalent than in several recently 
performed studies. The study was designed and performed at the same time as the 
IFN–ribavirin pivotal studies by Poynard et al. (9) and McHutchison et al. (10) and 
made use of the same brand of interferon and the same central laboratory for HCV 
RNA determination (17). Although our study did not include an arm with 12 months 
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IFN plus ribavirin, results for the 6 months combination treatment are comparable 
with those of 6 months in the above-mentioned studies, whereas results for 18 
months combination therapy in genotype 1 patients appear to be better than those 
reported for 12 months. When we compare the results of the studies with 6 months 
combination treatment, the results of the Benelux study are with 25% sustained 
response for genotype 1 and 72% for genotype 2/3 well within the range of 16%–
23% for genotype 1 and 50–69% for genotype 2/3 found in the pivotal studies. More 
specific, the relapse rate of 47% in genotype 1 and 19% in genotype 2/3 is 
comparable with the relapse rates of 44%, respectively, 19% in the only 6 months 
combination study from which details on relapse per genotype could be retrieved (8).  
Response and relapse rates for genotypes 2 and 3 do not change substantially by 
prolongation of treatment. However, for genotype 1 they do. Sustained response 
rates associated with IFN–ribavirin combination treatment in genotype 1 increase 
from 16–25% with 6 months therapy to 28–33% with 12 months therapy (8–10). The 
relative contribution of increased end-of-therapy response versus reduction of 
relapse is poorly defined, but in one study the relapse rate in genotype 1 patients 
after 12 months IFN–ribavirin combination therapy was still about 40% (25). In this 
Benelux study-arm with 18 months combination therapy, the relapse rate is reduced 
to 14%. This is not merely an effect of prolongation of the interferon part of the 
treatment, as prolongation of IFN monotherapy to 18 months reduces relapse in 
genotype 1 to only 40%. 
Do the benefits of prolonged treatment outweigh the additional costs and exposure of 
patients to potential side effects? Studies on combination therapy suggest that 
prolongation of treatment is especially cost-effective in patients with a poor response 
profile, like genotype 1 and/or a high viral load (28–30). In our study, 25% of patients 
withdrew from 18 months combination therapy prematurely because of side effects or 
noncompliance, which is comparable to the 21-27% reported by the pivotal studies 
(9, 10). Interestingly, most of the serious adverse events occurred in our study during 
the first 6 months of treatment, and only 2 cases were reported between month 12 
and 18. 
Are these observations still of value in the PEG-IFN era? Interestingly enough, 
combination treatment with PEG-IFN and ribavirin increases the on-treatment 
response and thereby the sustained response rates in genotype 1, but does not 
affect the relapse rates in a major way. Hadziyannis et.al (11) reported relapse rates 
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of 48% for 6 months therapy and 27% for 12 months, which is comparable to relapse 
rates with regular combination therapy. The highly significant reduction in relapse 
rate observed in our study led to a borderline significant 9–15% increase of sustained 
virological response. The effect of relapse reduction on the sustained response rate 
will increase as the percentage of end-of-treatment response increase, as it is now 
the case with pegylated–IFN–ribavirin combination. Therefore, prolongation of 
treatment might be a worthwhile option especially for patients with a poor response 
profile including the presence of cirrhosis and/or a high pretreatment viral load with 
genotype 1. These observations regarding the potential benefit of prolonged antiviral 
therapy in the PEG-IFN era are yet to be proven and should be explored in new 
prospective trials on prolonged therapy with pegylated interferons and ribavirin.  
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ABSTRACT 
 
Background and aims: Results of interferon-based treatments of chronic hepatitis C 
have markedly improved except for patients with unfavorable characteristics. To 
assess whether such patients can respond to modified interferon regimens we 
performed a meta-analysis on data of individual patients treated in our center with 
high-dose induction and prolonged daily interferon plus ribavirin. 
Methods: Fifty-four patients selected for poor-response characteristics such as 
genotype 1, cirrhosis or non-response to previous therapy were enrolled sequentially 
to one of three therapy schedules. Treatment consisted of 10 MU interferon-a2b 
(IFN) daily for 2–4 weeks followed by daily 3–5 MU IFN until week 52 and 3 MU daily 
or thrice weekly until week 76 in combination with ribavirin. 
Results: Sustained response rates varied between 75–83% for patients with 1 
unfavorable characteristic (n=23). In patients with combinations of such 
characteristics, sustained response rates were 60%, but only 21% for genotype 1 
and cirrhosis (n=14). Six patients (11%) stopped therapy because of adverse effects; 
clinically serious adverse events occurred in 2/7 patients with advanced cirrhosis. 
Conclusion: High-dose induction and prolonged daily interferon–ribavirin therapy is 
an acceptable and potentially highly effective treatment modality for selected patients 
with unfavorable characteristics such as genotype 1, cirrhosis or previous non-
response.  
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INTRODUCTION 
 
The interferon-based treatment of chronic hepatitis C has made remarkable progress 
over the past ten years. Since the introduction of pegylated interferon (PEG-IFN) 
ribavirin combination therapy, results of large international trials indicate cure-rates of 
77-82% in genotype 2 and 3 infection. However, the predominant genotype in many 
parts of the world is genotype 1 and the sustained response rate in this type of 
infection is still only 42-46% (1,2). 
Morbidity and mortality of chronic hepatitis C is predominantly in patients with 
cirrhosis (3). Responses in patients with cirrhosis are generally less than in those 
without cirrhosis although treatment with pegylated interferon diminishes the 
difference (4). It is therefore of note that the large trials of interferon–ribavirin 
combination as well as those assessing PEG-IFN with or without ribavirin comprised 
only a small number of patients with cirrhosis (1,2,5,6).  
For patients with unfavorable baseline characteristics, we started in 1998 a special 
treatment program of high induction dose (10 MU daily) of interferon (IFN) (7,8) 
followed by long-term daily IFN for 12-18 months in combination with ribavirin. To 
assess whether such treatment is still of clinical value for certain patient types in the 
era of PEG-IFN we performed a meta-analysis on individual treatment data of 54 
patients with unfavorable baseline characteristics such as genotype 1 or 4, cirrhosis, 
non-response to IFN or combinations of these criteria treated in our center with high-
dose induction and prolonged daily IFN plus ribavirin. 
Three treatment schedules of high dose induction and prolonged daily IFN in 
combination with ribavirin were used. The initial study (9) was designed to explore by 
viral kinetics the IFN induction dose leading to a maximal initial response. The 
patients were treated with a relative intensive and long induction regimen of IFN. 
Subsequently, two other regimens were designed to preserve the favorable results in 
terms of viral kinetics but to reduce the intensity in terms of side effects and costs. In 
all three protocols IFN was given daily during at least 12 months in order to maintain 
a constant drug level and thereby maximize viral inhibition and to minimize virological 
breakthrough. Thereafter, treatment was continued up to 76 weeks in an attempt to 
reduce viral relapse (10,11). 
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PATIENTS AND METHODS 
 
Study population 
Between February 1998 and March 2001, 55 consecutive patients with documented 
chronic hepatitis C were enrolled in a program of high dose induction and prolonged 
daily IFN in combination with ribavirin therapy. The ethical committee approved the 
study and patients gave written informed consent for inclusion. Patients were eligible 
if their maximal chance of reaching a sustained response with standard therapy was 
considered less than 30% according to the 1998 EASL consensus statement (12). 
Such patients had genotype 1 or 4, cirrhosis, non-sustained response to prior 
treatment or combinations of these criteria. In this study non-sustained response was 
defined as a positive HCV-RNA serum test after at least 6 months of IFN 
monotherapy (3 MU tiw) or a relapse after 12 months of IFN–ribavirin combination 
treatment. Patients with clinical relevant concomitant diseases were excluded 
according to criteria previously described (11,13). 
 
Figure 1 Study design 
 
IFN 5 MU/ day 
10 MU/ day 
10 MU/ day 
10 MU/ day 
5 MU/ day 
24 52 76 
weeks
4 0 2 
IFN 3 MU / day
IFN 3 MU / day
IFN 3 MU t.i.w.
Ribavirin 1 - 1.2 gram daily
Ribavirin 1 - 1.2 gram daily
IFN 3 MU / day
Ribavirin 1 - 1.2 gram daily
IFN 3 MU t.i.w. 
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Study design 
Patients were allocated successively to receive one of the following treatment 
regimens (Figure 1). The first 24 consecutive patients received 10 million units (MU) 
IFN-a2b (Intron A, Schering-Plough, Kenilworth, NJ, USA) daily for 4 weeks followed 
by 5 MU daily until week 24, 3 MU daily until week 52 and 3 MU thrice weekly until 
week 76 (group A). The next fifteen patients were assigned to receive 10 MU IFN-
a2b daily for 10 days followed by 3 MU daily until week 52 and 3 MU thrice weekly 
until week 76 (group B). The following 16 patients were assigned to receive 10 MU 
IFN-a2b daily for 2 weeks followed by 5 MU daily until week 4 and 3 MU per day until 
week 76 (group C). Ribavirin was supplied to all patients as 200-mg capsules given 
orally in 2 divided daily doses of 1,000 mg (weight <75 kg) or 1,200 mg (weight ≥75 
kg) throughout the entire treatment period.  
 
All patients were admitted to the ward for the first 7 days of treatment and thereafter 
intensively monitored on an outpatient basis. Clinical and biochemical assessments 
were conducted every 4 to 6 weeks during therapy and during a 6-month follow-up 
period. 
 
Dose adjustment was based on clinical intolerance, granulocytopenia below 0.5 x 
106/mm3 (IFN) or hemoglobin below 6 mmol/l (ribavirin). In such cases interferon was 
reduced to the next level of the treatment schedule, ribavirin was reduced by steps of 
200 mg/day. Combination therapy was discontinued in case of virological non-
response, defined as detectable HCV RNA at week 12. 
 
Histology 
All patients underwent liver biopsy before the start of therapy. An experienced 
pathologist who was unaware of the clinical outcome evaluated each liver biopsy for 
the presence of cirrhosis, comparable to Metavir F4. 
 
Virology  
Blood was drawn at baseline and at week 4, 12, 16, 24, 48, 76, 88 and 100. Blood 
samples were collected in plasma preparation tubes (Becton-Dickenson, Plymouth, 
UK), which were spun directly after collection in order to avoid RNA breakdown.  
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A qualitative HCV RNA assay was performed in a single local laboratory to assess 
viremia (Cobas Amplicor HCV test, Roche Diagnostics, Almere, The Netherlands). 
Genotypes were identified before the start of treatment by in-house sequence 
analysis. 
 
Descriptive analysis  
The primary end point of this analysis was the rate of sustained response after a 24-
week treatment free follow-up period. Results were calculated for the total population 
(intention-to-treat analysis). The breakthrough rate was calculated at the end of 
treatment for those reaching HCV RNA negativity during treatment and the relapse 
rate at 24 weeks of follow-up for those who were HCV RNA negative at the end of 
treatment. 
 
Statistics  
Data were analyzed using SPSS for Windows (Version 10.1 SPSS Inc, Chicago, IL, 
USA). Percentages are given with 95% confidence intervals (CI). 
 
RESULTS  
 
Patient characteristics  
In table 1, baseline characteristics of the study population are shown per treatment 
schedule and for the whole group. One patient, who was assigned to treatment 
regimen C and who had a sustained response, did on retrospect not comply with the 
inclusion criteria associated with poor response and was excluded from the analysis. 
The intention-to-treat population (ITT) consisted of 54 patients of whom 44 completed 
the study (81%) according to the protocol.  
The proportion of cases with cirrhosis was 46%. Genotype 1 was the predominant 
genotype (69%). More than half of the patients (54%) had a failure to prior IFN 
treatment. Fourteen patients (26%) had both a genotype 1 and cirrhosis. The majority 
of patients (81%) had a high viral load (≥ 2 x 106 copies/ml). 
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Table 1 Baseline characteristics of the patients (intention-to-treat cohort) 
Treatment regimen Characteristica
Group A 
(n=24) 
Group B 
(n=15) 
Group C 
(n=15) 
Total 
(n=54) 
 Age (yr) 46 ± 10 45 ± 7 45 ± 10 45 ± 9 
 Sex (M/F) 17/7 11/4 12/3 40/14 
 ALT (IU/l) 103 ± 83 125 ± 78 117 ± 51 113 ± 73 
Cirrhosis–n (%) 12 (50%) 1 (7%) 12 (80%) 25 (46%) 
Serum HCV-RNA 
 copies/ml 
 ≥ 2 x 106 –n (%) 
 
1.2x107
17 (71%) 
 
3.2x107
14 (93%) 
 
7.9x106
13 (87%) 
 
1.6x107
44 (81%) 
Genotype 
 1 & 4b (%) 
 2 & 3 (%) 
 
12 (50%) 
12 (50%) 
 
15 (100%) 
0 (0%) 
 
10 (67%) 
5 (33%) 
 
37 (69%) 
17 (32%) 
Prior treatment failure 15 (63%) 11 (73%) 3 (20%) 29 (54%) 
 
a Plus–minus values are means ± SD. 
b Only one patient had genotype 4. 
 
 
 
Outcome  
In table 2, intention-to-treat results are shown per treatment arm and for the total 
study population. The ITT sustained response rates were 67% (95% CI: 45-84%), 
53% (95% CI: 27-79%), 47% (95% CI: 21-73%) and 57%(95% CI: 43-71%) for 
respectively treatment regimen A, B, C and the total study population. The outcomes 
for the three treatment regimens were not significantly different according to 
multivariate logistic regression analysis performed to correct for differences in 
baseline characteristics and study groups.  
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Table 2 Treatment outcome by treatment regimen and for the total study 
population (Intention to treat analysis) 
Treatment regimena Group A 
n=24 
Group B 
n=15 
Group C 
n=15 
Totala 
n=54 
Non compliance 
(0 – 4 weeks) 
1 1 2 4/54 (7%) 
(2-18%) 
Non-response  
(at 12 weeks) 
2 5 3 10/54 (19%) 
(9-31%) 
Stop due adverse event  
(12 - 76 weeks) 
4 0 2 6/54 (11%) 
(4-23%) 
Breakthrough during treatment 0 1 1 2/54 (4%) 
(0-13%) 
Relapse after treatment b 1 0 0 1/32 (3%) 
(0-16%) 
Sustained response a 16  (67%) 
(45-84%) 
8  (53%) 
(27-79%) 
7  (47%) 
(21-73%) 
31/54 (57%) 
(43-71%) 
 
a numbers–n, (%), (95% CI). 
b The relapse rate was calculated at 24 weeks of follow-up for those who were HCV RNA 
negative at the end of treatment. 
 
 
 
 
Patients with either cirrhosis, genotype 1/4 or non-response to prior therapy had 
sustained responses in 44% (95% CI: 24-65%), 49% (95% CI: 32-66%) and 55% 
(95% CI interval: 36-74%) respectively. When only 1 unfavorable characteristic was 
present, sustained response rates varied between 75-83%. In patients with 
combination of such criteria, sustained viral response rates were 60% (95% CI: 32-
84%) for genotype 1 and previous non-response (n=15), but only 21% (95% CI: 5-
51%) for genotype 1 and cirrhosis (n=14) irrespective of the presence or absence of 
previous non-response (fig. 2).  
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Figure 2 Sustained response rates per baseline characteristic(s) associated with 
unfavorable response 
 
 Genotype 1 & 4 (n=37)
Prior Non-response
(n=29)
Cirrhosis (n=25)
83%
5/6
75%
6/8
25%
2/8
60%
9/15
50%
 1/2
17%
 1/6
77%
7/9
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The sustained response for 1 unfavorable characteristic varied between 75-83%, and for 2 
characteristics between 25-60%; the sustained response was 17% if 3 unfavorable 
characteristics were present. 
 
 
 
Virological non-response (detectable HCV RNA at week 12 or later) occurred in only 
10/54 (19%; 95% CI: 9-31%). Four patients were not compliant: they stopped in the 
first four weeks after discharge from the hospital. In six patients (11%; 95% CI: 4-
23%), therapy was stopped because of adverse effects (hepatic decompensation 
(n=2), depression (n=2), cardiac complaints (n=1) and Staphylococcus sepsis (n=1)). 
Both patients that developed decompensated liver disease, had advanced cirrhosis: 
according to the Child-Pugh classification their baseline scores were 6, but both had 
elevated bilirubin and low platelets (3). All other adverse effects occurred within the 
first 8 weeks of treatment.  
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DISCUSSION 
 
This study documents the efficacy rates of high dose induction and prolonged daily 
interferon plus ribavirin treatment in patients with baseline characteristics associated 
with poor response. Sustained response rates of 49%, 44% and 55% were observed 
for patients with either genotype 1, cirrhosis or non-response to previous therapy. 
Results with modern schedules of PEG-IFN-α and ribavirin yield similar percentages, 
but the baseline characteristics in our study population were vastly more unfavorable. 
In patients with combinations of these unfavorable criteria, sustained virological 
response rates were considerably decreased: 25% in patients with cirrhosis and 
genotype 1 and 17% in those who met all three criteria. 
 
The studies were originally designed to explore the optimal IFN-α induction dose by 
viral kinetics (9,14,15). The first group of patients was treated with an intensive 
schedule resulting in a sustained response rate of 67% (15). The next two strategies 
were attempts to decrease morbidity and cost without loosing efficacy. However, by 
shortening the induction period adverse effects were somewhat decreased but  the 
effectiveness was also reduced in some patients (14). No clear advantage of either 
treatment schedules B or C was found over treatment schedule A. 
 
How can these favorable results be explained? First, in all three treatment groups, 
therapy was started with a daily high-dose interferon “induction” period in order to 
reach early HCV-RNA negativity. Early viral response is a strong predictor for 
sustained response (1,15,16). In this study, 17 patients were HCV-RNA negative 
after 4 weeks of treatment. Fourteen of them had a sustained response (82%) as 
compared to 17 out of 37 patients (46%) who had their HCV RNA response after 
week 4. Second, given the short half-life of IFN, daily IFN injections were given to 
obtain a more constant drug level in order to optimize viral inhibition and minimize 
viral breakthrough. The importance of constant antiviral pressure has become more 
clear since the introduction of PEG-IFN with its prolonged half-life (1,2). Third, we 
prolonged the treatment duration in order to prevent relapse (10,11). As a result, the 
relapse rate could be reduced to less than 5% in this study.  
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The intensive treatment schedules were expected to be associated with an increased 
rate of intolerance and side effects. Due to intensive monitoring and supportive care 
the rate of non-compliance could be kept low. Clinically serious adverse effects 
occurred in 2 patients with impaired liver function due to advanced cirrhosis. Since 
the sustained response rate in patients with advanced cirrhosis was limited to 1 out 
of 7, we conclude that risks outweigh benefits in this category of patients. 
 
How should these results be implemented into future treatment schedules? The 
results of this study show that patients with either genotype 1, cirrhosis or non-
response to previous therapy can benefit from high daily dosing and prolonged 
therapy and this treatment still remains an excellent option. In cirrhotic patients with 
genotype 1 the indication to treat should be made on an individual basis in view of 
the response rate of about 20%. Patients with advanced cirrhosis, in our view, should 
not be treated with this intensive regiment.  
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Chapter 9 
In this thesis a decade of clinical research on chronic hepatitis C is described. At the 
beginning, around 1990, the disease entity was clearly established but the hepatitis C virus 
was only identified the year before and serologic tests were just making their entrance (1,2). 
Interferon had been tested in non-A, non-B chronic viral hepatitis and found to induce 
normalization of serum transaminases in 50% of patients with persistence of serum ALT 
normality after stopping interferon therapy in 25% (3,4). The interferon trials were conducted 
with a fixed dose (2-3 Mega Units, three times a week) and fixed duration (6 months). 
 
The hypothesis was formulated that the initial response might be higher with a two- to three-
fold increase of the dose of interferon, and that relapse could be reduced by prolonging the 
duration of treatment according to the individual need.  
 
Academic centers were eager to conduct clinical research parallel to pharmaceutical 
industry-driven trials; pharmaceutical companies were willing to provide financial support for 
consortia of academic units. Physicians in hepatology became aware of the necessity to 
enter a large number of patients into a trial in order to show differences in response of 15% 
or less. The need for multicenter studies became apparent.  In that setting the Benelux 
studies on the treatment of chronic viral hepatitis C started with study 90-01. 
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Benelux study HCV 90-01 
Precise aim  
- enhance efficacy of standard interferon therapy by double IFN dose initially 
- individualized treatment guided by ALT and HCV RNA response 
Number of centers, number of patients 
- 19 centers, 354 patients randomized, 336 treated 
Two arms 
- standard: IFN-a2b, 3 MU tiw, 6 months 
- experimental: 6 MU tiw, 8 weeks, followed by downward titration to 3 and 1 MU tiw if 
ALT remained normal and treatment withdrawal if  ALT remained normal and HCV 
RNA undetectable on at least 2 occasions during at least 8 weeks 
Outcome measure 
- primary: sustained ALT and HCV RNA response 6 months after treatment 
- secondary: on-treatment HCV RNA and ALT response; predictors of response; 
change in histological activity index pre- versus post-treatment 
Results 
- SR (HCV RNA + ALT): 14% (9-21) standard vs 15% (10-21) experimental treatment 
- HCV RNA response week 4: 37% standard vs 47% experimental (p=0.02) 
- independent predictors of response: 1) pre-treatment: absence of cirrhosis, genotype 
2/3, low viral load, 2) per-treatment: HCV RNA week 4 (negative predictive value 
98.3%) 
- paired pre- and post treatment biopsies could be retrieved for central scoring in 126 
cases: SR response patients showed less (16%) progression of fibrosis than relapse 
(21%) or non-response (31%) patients; experimental therapy showed less (16%) 
progression of fibrosis than standard therapy (33%) 
Implications 
- an early HCV RNA response is a prerequisite for long-term efficacy 
- doubling the interferon dose increases the initial response 
- subsequent downward titration negates this effect, especially in genotype 1 
- IFN treatment inhibits the progression of fibrosis, even in patients without a sustained 
response 
 
 
 
 
 
While the Benelux study 90-01 explored a higher initial dose of interferon to increase the 
early biochemical and virological response, and adjusted the duration of therapy to the 
individual need to reduce relapse, new developments took place in other areas of the world. 
 
In Japan elaborate dose response studies are the initial step in clinical evaluation and initial 
virological response up to 90% were reported with daily doses of 10 mega-unit of interferon 
(5). Since the total dose of interferon was fixed, the duration of therapy was short; the 
relapse rate was high.  
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In Sweden and the USA ribavirin, a nucleoside analogue licensed for suppressing another 
RNA virus: RSV (respiratory syncitial virus), was in evaluation in view of its efficacy in 
reducing serum ALT (6–8). Neither histological improvement nor reduction in plasma 
HCVRNA could be demonstrated and the interest in the drug was fading 
 
In Italy standard interferon therapy (3 x week 3 Mega Units) was combined with ribavirin; a 
very important synergistic effect was reported in a single center uncontrolled study in 7 
patients (9). The need to study combination therapy in a controlled manner was evident, as 
well as exploring whether daily high dose interferon could induce an early virological 
response in those not responding to standard 3x week 3 mega-units. Both concepts were 
tested in two subsequent Benelux studies (91-04, 91-07) in patients that came out the 90-01 
study because of non-response. 
 
 
 
 
 
 
 
 
Benelux study HCV 91-04 
Precise aim 
- can daily high dose IFN induce HCV RNA response in patients who are resistant to 
standard IFN treatment? 
Number of centers, number of patients 
- 3 centers, 22 HCV patients without ALT response during previous therapy 
- subset of 10 virologic non-responders studied with frequent plasma sampling at 1 site
One arm 
- 10 MU IFN daily for 5 days, 10 MU t.i.w. until week 4, followed by stepwise dose 
reduction in case of response or withdrawal in case of non-response 
Outcome measure 
- primary: sustained HCV RNA response, 6 months after the end of treatment 
- secondary: early viral kinetics; predictors of response 
Results 
- sustained HCV RNA response in 4/22 patients (18%) 
- 9/10 patients studied with viral kinetics had a ≥2 log drop in viral load at week 4 
- predictors of SR were absence of cirrhosis, temporary viral response at previous 
therapy, and undetectable HCV RNA at week 4 (positive predictive value 80%, 
negative predictive value 100%) 
Implications 
- an early (week 4) HCV RNA response is a prerequisite for long-term efficacy 
- true resistance to interferon is rare, other factors are involved in non-response to 
therapy which should be explored 
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Benelux study HCV 91-07 
Precise aim 
- can ribavirin as monotherapy or in combination to interferon enhance the disappe-
arance-rate of plasma HCV-RNA and/or ALT normalization rate in patients who did 
not respond to Interferon therapy 
Number of centers, number of patients 
- 16 centers, 121 patients randomized, 117 treated 
Three arms 
- 6 months combination therapy with IFN 3MU tiw and ribavirin 1000-1200 mg/d 
- 6 months mono therapy with ribavirin 1000-1200 mg/d 
- 6 months mono therapy with ribavirin placebo 
Outcome measure 
- primary: sustained HCV RNA response, 6 months after the end of treatment 
- secondary: HCV RNA and ALT response; acceptability and safety 
Results 
- end of therapy response 35% and sustained HCV RNA response 15% in combination 
therapy vs no response in ribavirin mono therapy or placebo 
- on-treatment ALT response 58% in combination therapy, 23% in ribavirin, and 8% in 
placebo; sustained in 18%, 3%, and 3%, respectively 
- withdrawal for side effects or non-compliance 13% of patients on combination 
therapy, 13% of those on ribavirin, and 11% of patients on placebo; mean decrease 
of Hb in ribavirin mono and combi therapy 15% 
Implications 
- interferon and ribavirin combination therapy has additional effectiveness in non-
responders to IFN mono therapy 
- a large part (almost 60%) of the response on combination therapy is lost when 
treatment is withdrawn at 6 months; longer treatment duration might be needed 
 
 
 
Treatment results improved markedly with the introduction of ribavirin in 1993, and many 
small studies were started worldwide to evaluate the efficacy of combination therapy in non-
responders and relapsers to prior IFN mono therapy and in naïve patients. A meta-analysis 
of individual patient data comprising more than 90% of the published data till 1997 showed 
that the efficacy of combination therapy was enhanced 2-3 fold over mono therapy, leading 
to a sustained response in about 50% of naïve patients and relapsers and in about 15% of 
non-responders to prior IFN monotherapy (10).  
 
Although these results meant a major step forward for patients with chronic hepatitis C, still 
50% of them had no long-term benefit from therapy. Awaiting further potential treatment 
improvements by modifications of dose and duration, it was important to identify in an early 
stage of treatment those patients who would eventually prove to be treatment failures, so that 
costs and unnecessary exposure to treatment and its potential side effects could be reduced 
and alternative therapies could be offered in an early stage. In 1997, both the European and 
the US consensus statements recommended to use a lack of ALT normalisation at 12 weeks 
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as a stopping rule (11,12). Although this criterium identified over 90% of eventual non-
responders in an early stage, it also could lead to premature treatment withdrawal in almost 
20% of potential sustained responders. Early Benelux studies (13,14) pointed to the 
importance of an early week 4 HCV RNA response. This criterium was evaluated in a large 
group of patients treated in Benelux studies 90-01 and 91-07. 
 
 
 
Early prediction of response (Benelux studies HCV 90-01 and 91-07) 
Precise aim 
- to compare the predictive value for non-response of an early HCV RNA determination 
at week 4 with the standard week 12 ALT determination (recommended by the 
European and US consensus in 1997) in interferon monotherapy and in IFN ribavirin 
combination therapy 
Number of centers, number of patients 
- IFN monotherapy: 19 centers, 336 patients, 280 with a complete set of HCV RNA 
data at week 4 and ALT data at week 4, 8 and 12 
- IFN ribavirin combination therapy: 16 centers, 40 patients, 31 with a complete data 
set of HCV RNA at week 4 and ALT at week 4, 8 and 12 
Three arms 
- IFN monotherapy: standard 3 MU IFN tiw for 6 months or experimental 6 MU tiw for 8 
weeks followed by downward titration (study HCV 90-01) 
- IFN ribavirin combination therapy: 3 MU IFN tiw in combination with 1000-1200 mg 
ribavirin daily, for 6 months (study HCV 91-07) 
Outcome measure 
- predictive value for non-response by week 4 HCV RNA (detection limit 103 copies/ml) 
and week 12 ALT 
- fraction of potential responders lost if the test is used as a stopping rule 
Results 
- predictive value for non-response by week 4 HCV RNA: 99% (std IFN), 97% (exp 
IFN) and 100% (IFN ribavirin combi); by week 12 ALT: 97%, 91% and 95%, 
respectively 
- fraction of potential responders lost if week 4 HCV RNA is used as stopping rule: 5%, 
12% and 0%; if week 12 ALT is used: 10%, 28% and 20%, respectively 
Implications 
- use of a week 4 HCV RNA leads to a better prediction of non-response and a lower 
rate of missing potential responders than a week 12 ALT 
- an early (week 4) HCV RNA response is a prerequisite for long-term efficacy 
 
 
 
After the publication of two large pivotal trials in 1998 (15, 16), combination of IFN 3 MU tiw 
and ribavirin 1000-1200 mg/day became the standard treatment of chronic hepatitis C.  
Twenty-four weeks of combination therapy proved to be sufficient for genotypes 2 and 3, 
leading to sustained responses in 70-80% of patients, with no additional improvement after 
prolongation of therapy. However, for genotype 1 sustained response rates after 24 weeks of 
combination reached only up to 20%, due to limited on-treatment response and high relapse 
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rates up to 50% after treatment withdrawal (17).  On-treatment responses did not improve by 
prolonging treatment to 48 weeks, but relapse rates were reduced, leading to sustained 
response rates around 30% in genotype 1. In the era of IFN monotherapy, further reduction 
of relapse rates were shown to be accomplished by prolonging treatment to 18 or even 24 
months (18,19). The next logical step for the Benelux group was therefore to explore the 
possibility of further increasing combination treatment efficacy by prolonging treatment 
duration beyond 12 months.  
 
 
 
Benelux study HCV 96-01 
Precise aim 
- can we reduce the high relapse rate after 6 months IFN ribavirin combination therapy 
by prolonging the treatment to 18 months 
Number of centers, number of patients 
- 25 centers, 300 patients randomized, 295 started treatment 
Three arms 
- IFN 3 MU tiw + ribavirin 1000-1200 mg/day, 6 months 
- IFN 3 MU tiw + ribavirin 1000-1200 mg/day, 18 months 
- IFN 3 MU tiw + ribavirin placebo, 18 months 
Outcome measure 
- undetectable HCV RNA at the end of treatment and after 6 months follow-up 
- HCV RNA response during treatment 
Results 
- HCV RNA is undetectable at the end of treatment in 55% and 49% after 6 and 18 
months combination therapy, and in 26% after 18 months monotherapy (p<0.001) 
- relapse rates are 38% after 6 months combination therapy, 38% after 18 months 
mono therapy and only 13% after 18 months combination therapy (p=0.002) 
- sustained rate 34% for 6 months combination therapy, 16% for 18 months mono 
therapy, and 43% for 18  months combination therapy (p<0.05) 
- more than 80% of the virologic responses (HCV RNA ≤ 102 copies/ml) on 
combination therapy and 70% of those on monotherapy occurred within the first 3 
months of treatment 
- relapse rates in the poor response categories (genotype 1, high viral load, cirrhosis) 
were significantly higher than the relapse rates of the favourable categories for 18 
months monotherapy and 6 months combination therapy but approached the results 
of the favourable groups for 18 months combination therapy 
- prolongation of combination therapy from 6 to 18 months does not significantly 
influence the relapse (19 v 13%) and sustained response rates (72 v 64%) in 
genotype 2 and 3 
Implications 
- relapse rates of 15% or less are feasible by prolongation of IFN ribavirin treatment to 
18 months 
- prolongation of treatment is especially worthwhile in patients with a poor response 
profile, like genotype 1, high viral load, and/or cirrhosis 
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Treatment of patients with genotypes 2 or 3 appears no longer a major issue in view of the 
high efficacy of 24 weeks combination therapy. However, even with prolonged treatment, 
sustained response rates were still limited in patient categories that need therapy the most, 
like genotype 1, high viral load, and cirrhosis. In addition, re-treatment with combination 
therapy of prior non-responders to IFN mono therapy led to a limited success of only about 
15%. For these patients with a poor response profile, especially genotype 1, cirrhosis or prior 
treatment failure, a series of exploratory studies were performed, combining the concepts of 
induction therapy to increase the initial / early response, daily dosing to reduce breakthrough, 
prolonged treatment to reduce relapse, in combination with ribavirin. These series also 
formed the source for our studies on viral kinetics in combination therapy (20). 
 
 
 
HIRO studies 
Precise aim 
- assess whether combination therapy with high dose induction and prolonged daily 
IFN and ribavirin leads to an increased sustained response in difficult to treat 
patients, characterized by genotype 1, cirrhosis and/or non-response or relapse to 
previous therapy 
Number of centers, number of patients 
- single center, 55 consecutive patients with a poor response profile enrolled and 54 
treated in three sequential cohorts; meta-analysis of individual patient data 
Three arms 
- first cohort (n=24): IFN 10, 5 and 3 MU daily until week 4, week 24 and week 52, 
respectively, followed by 3 MU tiw until week 76, in combination with ribavirin 1000-
1200 mg/day 
- second cohort (n=15): IFN 10 and 3 MU daily until day 10 and week 52, respectively, 
followed by 3 MU tiw until week 76, in combination with ribavirin 1000-1200 mg/day 
- third cohort (n=15): IFN 10, 5 and 3 MU daily until week 2, week 4 and week 76, 
respectively, in combination with ribavirin 1000-1200 mg/day 
Outcome measure 
- primary: sustained HCV RNA response 6 months after treatment withdrawal 
- secondary: breakthrough and relapse rates; tolerability; factors associated with 
response 
Results 
- sustained response total group 57%; ca. 80% if only 1 unfavorable factor, ca. 20% for 
the combination of (advanced) cirrhosis and genotype 1 or 4 
- low breakthrough (4%) and relapse (3%) rates 
- low drop-out rate for non-compliance (7%) and adverse events (11%); clinically 
serious adverse events occurred in 2 patients with advanced cirrhosis (characterized 
by low platelets and elevated bilirubin) 
Implications 
- patients with genotype 1, cirrhosis and/or prior treatment failure can benefit from 
prolonged treatment with high dose daily interferon and ribavirin 
- the additional value of an induction phase followed by dose reduction has not (yet) 
been established and should be further explored; however, low breakthrough rates on 
dose reduction were observed in this exploratory study 
- patients with advanced cirrhosis should not be treated with this intensive regiment 
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IFN has a short half-life of only 7 hours (21), and dosing thrice weekly leads to large 
fluctuations in antiviral pressure, reducing the chances of an early viral response and 
increasing the chances of a breakthrough during therapy (22). The beneficial effect of 
reducing fluctuations in IFN levels, acquired in our studies by daily dosing, was also 
observed with the introduction of the long-acting pegylated interferons with prolonged 
absorption half-lives up to 50 hours and elimination half-lives between 60 and 70 hours(23, 
24). With PEG-IFN ribavirin combination therapy, sustained response rates in genotype 1 
have increased to almost 50%, mainly as a result of an increase of the on-treatment 
response. The relapse rate after 12 months treatment is, however, still high – up to 30% 
(table 1) – and new studies should explore the possibility of reducing relapse by prolonged 
treatment, shown to be of value in the Benelux studies with standard IFN and ribavirin. 
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 Table 1 Reported relapse and sustained response rates in genotype 1 and 
genotypes 2/3 for (PEG) IFN monotherapy and combination with ribavirin, according 
to treatment duration 
  
Relapse‡ 
 
Sustained 
response 
Author Treatment schedule† g1 g2/3 g1 g2/3 
      
 IFN monotherapy     
Reichard 1998(17) 3x3 IFN-a2b, 6 mo 78% 63% 9% 23%
McHutchison 
1998(16) 3x3 IFN-a2b, 6 mo   2% 16%
Poynard 1998(15) 3x3 IFN-a2b, 12 mo   11% 33%
McHutchison 
1998(16) 3x3 IFN-a2b, 12 mo   7% 29%
Benelux study(25) 3x3 IFN-a2b, 18 mo 40% 40% 13% 26%
      
 PEG-IFN monotherapy     
Lindsay 2001(26) 1.5 ug/kg PEG-a2b, 12 mo 66% 36% 14% 49%
Fried 2001(27) 180 PEG-a2a 12 mo   21% 45%
      
 IFN + Ribavirin combi therapy     
Reichard 1998(17) 3x3 IFN-a2b + Rbv 1000-1200, 6 mo 44% 19% 23% 50%
Poynard 1998(15) 3x3 IFN-a2b + Rbv 1000-1200, 6 mo   18% 64%
McHutchison 
1998(16) 3x3 IFN-a2b + Rbv 1000-1200, 6 mo   16% 69%
Benelux study(25) 3x3 IFN-a2b + Rbv 1000-1200, 6 mo 47% 19% 25% 72%
      
Poynard 1998(15) 3x3 IFN-a2b + Rbv 1000-1200, 12 mo   31% 64%
McHutchison 
1998(16) 3x3 IFN-a2b + Rbv 1000-1200, 12 mo   28% 66%
Manns 2001(28) 3x3 IFN-a2b + Rbv 1000-1200, 12 mo   33% 79%
Mangia 2002(29) 3x3 IFN-a2b + Rbv 1000-1200, 12 mo 42% 11% 19% 61%
Fried 2001(27)  3x3 IFN-a2b + Rbv 1000-1200, 12 mo   37% 61%
      
Benelux study(25) 3x3 IFN-a2b + Rbv 1000-1200, 18 mo 14%¶ 13% 37% 64%
      
 PEG-IFN + Ribavirin combi therapy     
Hadziyannis 2002 
(30) 180 PEG-a2a + Rbv 1000-1200, 6 mo 48% 12% 41% 78%
Manns 2001(28) 1.5 ug/kg PEG-a2b + Rbv 800, 12 mo   42% 82%
Fried 2001(27)  
180 PEG-a2a + Rbv 1000-1200, 12 
mo   46% 76%
Hadziyannis 2002 
(30)
180 PEG-a2a + Rbv 1000-1200, 12 
mo 27% 9% 51% 77%
 
‡ Virological relapse could only be calculated for those studies which gave detailed 
information on both end-of-treatment response and sustained response rates in genotype 
1 and genotype 2/3 patients; g1: HCV genotype 1; g2/3: HCV genotype 2 or 3 
† Treatment schedule: IFN dose in MU per week; PEG-IFN dose in ug per week; 
Ribavirin dose in mg per day 
¶ Intention to treat 14% (95% C.I. 3.9%-31.7%), per protocol 4% (95% C.I.  0.0%-20.3%) 
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What is the biological background of these observations? Viral kinetics during 
treatment with IFN show a fast initial decline in viral load followed by a slower second 
phase (31–33); similar observations were made with PEG-IFN (34). 
Biomathemathical analysis of these patterns shows that the initial viral decline is 
related to the efficacy by which interferon blocks the intracellular viral replication of 
HCV. This efficacy (ε) is dependent on the dose of interferon used (22,32,35,36) and 
on the genotype present (37). The second phase of viral decline is also dependent 
on the blocking efficacy (ε) of IFN (38), but its major determinant is the immune 
mediated removal of virus producing cells (δ). A significant influence of Ribavirin on 
early viral kinetics has not been established (36,39). The infected cell loss rate (δ) is 
the best predictor of sustained response (40), and its major determinants are the 
genotype (34,37) and the pretreatment viral load (37,38). Patients with a genotype 2 
or 3 have, besides a higher blocking efficacy (ε) of IFN, a higher infected cell loss 
rate (δ) than patients with genotype 1 (37), which explains the low relapse rates and 
the lack of benefit by prolongation of combination therapy beyond 6 months. In 
contrast, the infected cell loss rate (δ) is significantly lower in genotype 1 and here a 
major benefit in reducing relapse rates can be obtained by prolonging treatment. The 
observation that the infected cell loss rate (δ) is also determined by the pretreatment 
viral load (37,38) is in accordance with our findings in the Benelux study 96-01 that 
the pretreatment viral load is the major predictor of relapse for genotype 1 patients. 
Genotype 1 patients with a high viral load will therefore benefit the most from 
prolonging treatment duration. 
 
Further improvement of treatment results might be acquired by individualization of 
therapy based on the early viral response. The importance of an early viral response 
is still valid, but the definitions have to be modified in view of the improved detection 
limits of HCV RNA assays. With a detection limit of 103 copies / ml, used in the 90-01 
and 91-07 studies, a detectable HCV RNA at week 4 almost precluded the chance of 
reaching a sustained response. With the more sensitive test of 102 copies / ml, used 
in the 96-01 study, a substantial number of eventual sustained responders lost 
detectable virus between week 4 and 12. It is therefore logical to use quantitative in 
stead of qualitative criteria, and a stopping rule of less than 2 log decrease in the first 
12 weeks is advocated nowadays (41).  
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Even earlier and maybe better individualization might be derived by assessing viral 
kinetics during the first weeks (42) or even after a single dose of IFN (43).  
 
However, it would not be prudent to recommend a strategy based on virological 
characteristics alone. Besides other independent factors of response, like age, sex, 
fibrosis and steatosis (44), one of the most important determinants of success is 
patient compliance (45). Large discrepancies exist between the results of therapy of 
the registration trials and the overall results in general practice (46). Side effects like 
flue-like symptoms, depression and anemia can now effectively be managed by 
appropriate drugs, but the major determinant of success is motivation and continuous 
education, not only of the patient and his relatives but also of the people involved in 
giving the treatment. And, in the end, teamwork was essential for the success of the 
Benelux studies and will remain essential for the treatment of individual patients. 
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 DANKWOORD 
 
Het doen van multicenter studies betekent samenwerken. Ik realiseer me dat 
samenwerken met mij niet altijd eenvoudig was. Mijn hang naar perfectie heeft 
sommigen wellicht soms tot wanhoop gedreven. Vaak moest het (in mijn optiek) net 
nog een beetje beter en dan meestal op het laatste moment. Desondanks is de 
periode van samenwerking binnen de Benelux studies zeer stimulerend geweest en 
zijn er vele mooie dingen uit voortgekomen. 
 
Allereerst wil ik natuurlijk Solko Schalm bedanken, niet alleen omdat hij me begeleid 
heeft om uiteindelijk toch te promoveren, maar met name ook voor de vele jaren van 
interactie die voor mij zeer leerzaam zijn geweest. Solko, ik heb bewondering voor je 
gedrevenheid en organisatietalent. Je neiging om alles nog net een tandje beter te 
krijgen, kostte soms de nodige energie maar leidde altijd wel tot fraaie resultaten. Je 
rol als mede-initiator van de Benelux groep is essentieel geweest. Er is veel werk 
verzet in de afgelopen jaren en ik heb goede herinneringen aan de samenwerking 
met je binnen de vele projecten die er waren op locaal, nationaal en internationaal 
niveau. Ten slotte koester ik goede herinneringen aan de vele donderdagavonden bij 
jou thuis waar het harde werken steevast werd beloond met een mooi glas rode wijn. 
(staat de vereniging OWIOZ nog open voor nieuwe leden?). Daarbij wil ik ook Atie 
bedanken voor de vele momenten van gastvrijheid.  
 
Ik wil alle patiënten bedanken die bereid waren te participeren in de studies. 
Natuurlijk was het doel steeds om voor hen de meest optimale therapie te vinden, 
maar het kost soms toch ook vertrouwen (en moed) als jouw arts na het falen van 
een vorige zware kuur voorstelt om het nog eens te proberen, maar nu nog wat 
intensiever.  
 
Met plezier kijk ik terug op de samenwerking met de vele collega’s en vrienden uit 
België, Nederland en Luxemburg. De meetings in de E10 Hoeve, net over de grens 
in België, waren altijd inspirerend. Velen heb ik leren waarderen, niet alleen als arts 
of wetenschapper, maar ook als mens. Johan Fevery en Andre Elewaut, ik beschouw 
jullie naast Solko als mede-grondleggers van de studiegroep, waarvoor mijn dank.  
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 Frederik Nevens, het samenwerken met jou was altijd van hoog niveau. Ik waardeer 
je zeer om jouw intelligentie, organisatietalent en warme menselijkheid. Peter 
Michielsen, Richard de Vries, Pieter Wismans, Carin van Nieuwkerk, Bart van Hoek 
en Jannie den Ouden, dank dat we altijd op jullie konden rekenen. Marc Hautekeete: 
je was helaas veel te kort bij ons, op sommige momenten meen ik nog steeds je 
gulle lach te horen.  
 
Dat de taalgrens geen barrière hoeft te zijn voor samenwerking, bewezen de vele 
Franstalige collega’s, met wie ik dank zij mijn beperkte talenknobbel voornamelijk in 
het Engels communiceerde. Michael Adler, Nadine Bourgeois, Reginald Brenard, 
Jean Pirotte, Jean Delwaide, Jean Henrion, C de Galocsy en vele anderen hebben 
een belangrijke bijdrage geleverd en waren trouw in het bezoeken van de meetings. 
Vanwege de reisafstand verliep het contact met de collega’s Weber en Arendt in 
Luxemburg meer elektronisch dan fysiek, maar de bijdrage was er niet minder om en 
de spaarzame momenten dat we elkaar zagen waren nuttig. 
 
De samenwerking met de verschillende centra in de Benelux is altijd een boeiend 
proces geweest. Als Benelux groep vonden we het belangrijk om ernaar te streven 
steeds maar één klinische studie tegelijkertijd te doen, zodat deze snel aan zijn 
beoogde recruitment kwam waarna een nieuwe studie kon worden geïnitieerd.  
 
Terwijl de bereidheid tot samenwerking vanuit België en Luxemburg steeds 
overweldigend was, evenals die vanuit vele Nederlandse ‘perifere’ centra, was de 
samenwerking tussen de Nederlandse universiteiten in de loop der jaren sterk 
wisselend. Desondanks heb ik goede herinneringen aan de contacten met de andere 
Nederlandse universitaire centra, met name aan de groepen van Rob Chamuleau en 
Henk Reesink, en aan die van Jan van Hattum, zowel tijdens perioden van hechte 
samenwerking als tijdens perioden waar ieder organisatorisch zijns weegs ging. 
 
Dank ook aan de vele jonge onderzoekers die vaak het meeste werk achter de 
schermen verrichten, zoals Frank Bekkering, Hans van Vlierberghe en Christine 
Weegink, en de mensen die sterk betrokken waren bij de vervolgstudies, zoals Jan 
Maarten Vrolijk en Bart Veldt.  
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 Alle basale wetenschappers van het eerste uur, dank voor jullie fantastische inzet. Ik 
realiseer me dat we de eerste Benelux trial hebben opgezet in een tijd dat de PCR 
techniek nog volledig moest worden ontwikkeld. Met een patiënten aanbod van meer 
dan 350 en een PCR capaciteit in de beginperiode van slechts enkele tientallen per 
week hebben jullie een enorme klus geklaard. Daarbij lag onze nadruk soms teveel 
op kwantiteit maar die van jullie steeds op kwaliteit, op een verdere verdieping en 
betering. De mensen van het eerste uur, zoals Bernhard Kleter, Leen Jan van Doorn, 
Ruud Heijtink, Bert Niesters, Wim Quint, Nico Lelie en Theo Kuipers, hebben hierbij 
heel veel belangrijk werk verzet.  
 
Ook de wetenschappers op andere vlakken hebben een onschatbare bijdrage 
geleverd, zoals Fibo ten Kate en Carolien Bronkhorst die niet alleen vele uren 
hebben besteed aan het classificeren van de biopten maar daarnaast ook 
gewaardeerde gesprekspartners waren op de meetings. Geert Leroux-Roels die een 
aantal fraaie ancillary studies heeft opgezet en deze ook succesvol heeft afgerond, 
Wim Hop en Bettina Hansen die altijd bereid waren hun hersenen op de meest 
onmogelijke tijden te doneren aan de wetenschap. 
 
De mensen van het trialbureau en het secretariaat zorgden achter de schermen dat 
alles goed liep. Dat ging niet altijd automatisch, er is heel wat gezwoegd en 
gesteund. Ik heb bijzondere waardering voor jullie inspanning, jullie waren de motor 
die het project nodig had. Vele mensen zijn in de loop van de jaren langsgetrokken, 
mogelijk dat ik er enkele vergeet. Willeke Beukman, je hebt jarenlang de studies op 
een geweldige manier ondersteund en je was nooit te beroerd om op het laatste 
moment over te werken om alles toch nog op tijd klaar te krijgen. Jan Boot, er was 
altijd wel nood, dank voor al je programmeerwerk. Elke Verheij, dank zij jou heeft het 
trialbureau aan professionaliteit gewonnen. De mensen van de clinical research unit, 
de verpleging, de trial nurses, het poli personeel en in het bijzonder ook Heleen van 
Santen, dank voor al jullie ondersteuning, niet alleen van de projecten maar met 
name ook van de patiënten; patiëntenzorg is teamwork, en jullie vormen daarin een 
essentiële schakel. Ook dank aan de vele anderen, zoals Sylvia de Vlaming, Mieke 
Pruijsten, Margriet Leeuwesteijn, Marion Hoogendoorn, die stuk voor stuk altijd klaar 
stonden om te helpen. 
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 Ik wil ook alle collega’s van de hepatologie groep in Rotterdam bedanken waarmee ik 
vele jaren met plezier heb samengewerkt. Rob de Man, Herold Metselaar, Sjoerd de 
Rave, Harry Janssen, het waren interessante tijden waarin de afdeling hepatologie 
en levertransplantatie in 10 jaar tijd een enorme groei heeft doorgemaakt. Henk van 
Buuren, paranimf en gewaardeerd collega, ondanks alle drukte had je altijd tijd voor 
iedereen; de plezierige momenten op je kamer, als besluit van een drukke week, 
onder het genot van wat wijn uit een plastic bekertje, ze zullen me nog lang heugen. 
 
Ook de collega’s van de ‘holle buizen’ sectie wil ik bedanken voor de leerzame 
momenten, in het bijzonder Jan Dees en Jelle Haringsma die mij voorafgaand aan 
mijn overstap naar Delft hebben geholpen mijn endoscopische vaardigheden weer 
helemaal op peil te brengen. Voor Ernst Kuipers heb ik grote waardering zoals hij in 
relatief korte tijd Rotterdam weer helemaal op de kaart heeft gezet binnen 
gastroenterologisch Nederland. Beste Ernst, ook dank voor de manier waarop je mij 
gestimuleerd hebt tot reflectie, waardoor ik keuzes heb gemaakt in mijn carrière waar 
ik tot nu toe geen spijt van heb. Ik hoop ook in de toekomst op een goede band 
tussen Rotterdam en Delft op gebied van patiëntenzorg, onderwijs en onderzoek. 
 
Mijn collega’s in Delft wil ik bedanken voor de ruimte die ik kreeg, binnen het 
overvolle programma, om het proefschrift af te ronden. Ik heb me vanaf het begin bij 
jullie thuis gevoeld en waardeer jullie combinatie van professionaliteit en 
menselijkheid. In het bijzonder wil ik mijn directe MDL collega’s bedanken, Joost 
Scherpenisse, Clemens Bolwerk, tevens paranimf, en Willemien Erkelens, en de 
MDL collega’s in internisten-vermomming, Herman Walinga en Iwan Meynaar, voor 
de altijd plezierige samenwerking en de hoge mate van collegialiteit.  
 
Daarnaast zijn er nog vele andere collega’s, teveel om op te noemen, die allemaal 
hun specifieke en gewaardeerde bijdrage hebben geleverd, leidend tot het succes 
van de diverse studies. Het feit dat jullie niet bij name zijn genoemd maakt de dank 
er niet minder om. 
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 Mijn vrienden en familie wil ik bedanken voor alle geduld die ze met me hebben 
gehad. Hoewel de intenties goed waren, waren de contacten in de praktijk vaak 
spaarzaam door de grote veelheid aan werk. Ik hoop dat daar nu enige verandering 
in komt. Peter die mij eens terzijde stond in de mist, Rick die mij altijd wist te 
stimuleren met de wijze woorden van Goethe, Marijke die mij zo nu en dan 
vriendelijke woorden zond, mijn tennisvrienden die altijd zorgden voor welkome 
onderbrekingen, ik waardeer jullie.  
 
Mijn vader, die mij veel te vroeg ontviel, en mijn moeder wil ik danken voor alle 
stimulans, mogelijkheden en liefde. Ze hebben me laten inzien dat we soms veel te 
druk zijn met kleine dingen en dat er veel belangrijker dingen in het leven zijn om je 
mee bezig te houden.  
 
En ten slotte mijn geliefden, Annemarie en de kinderen, Johan, Willem Pieter, 
Marlies en Hannah. Ik waardeer jullie enorm, en ik hoop………Wat ik hier op papier 
wilde zetten, kan ik veel beter in de praktijk waarmaken……..  
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 CURRICULUM VITAE 
 
De auteur van dit proefschrift werd geboren op 2 april 1958 te Vlaardingen. In 1976 
behaalde hij het VWO diploma aan het CSG Westland-Zuid te Vlaardingen. Tijdens 
zijn studie geneeskunde aan de Erasmus Universiteit te Rotterdam deed hij 
gedurende een half jaar onderzoek aan het Albert Einstein College of Medicine in 
New York. In 1983 behaalde hij zijn artsexamen (Cum Laude). Voor het vervullen 
van zijn militaire dienstplicht was hij gedetacheerd in het Militair Hospitaal ‘Dr. A. 
Mathijsen’ te Utrecht, waar hij werkte op de afdelingen cardiologie en intensive care. 
In 1985 begon hij zijn opleiding tot internist in het St Clara Ziekenhuis te Rotterdam 
(opleider dr. J. Bruins Slot) waarbij hij vanaf 1990 een stage gastro-enterologie/ 
hepatologie volgde op de afdeling Inwendige Geneeskunde II van het Academisch 
Ziekenhuis Rotterdam/Dijkzigt (hoofd prof. J.H.P. Wilson). In 1991 werd hij 
ingeschreven in het specialistenregister als internist. Van 1991 tot 2002 was hij 
werkzaam als staflid in het Academisch Ziekenhuis Rotterdam, eerst op de 
eerdergenoemde afdeling Inwendige Geneeskunde II en vanaf 1998 op de afdeling 
Maag-, Darm- en Leverziekten (hoofd ad interim prof. dr. S.W. Schalm, vanaf 
augustus 2000 hoofd prof. dr. E.J. Kuipers). Hij werd in 2001 ingeschreven in het 
specialistenregister als maag-darm-leverarts. Vanaf 2002 tot heden is hij werkzaam 
als maag-darm-leverarts in de Reinier de Graaf Groep te Delft.  
Vanaf 1990 werden studies op gebied van virale hepatitis C verricht onder supervisie 
van en in nauwe samenwerking met prof. dr. S.W. Schalm. Hij was daarbij intensief 
betrokken bij het opzetten en uitvoeren van diverse studies in internationaal verband, 
hetgeen de basis vormde voor dit proefschrift. Hij was mede-initiator en coördinator 
van de Benelux studie groep (1990-2002); daarnaast was hij sterk betrokken bij twee 
Europese onderzoeksprojecten, EUROHEP (1991-1999) en DITTO HCV (2000-
2002). 
Hij is gehuwd met Annemarie en heeft vier kinderen, Johan, Willem Pieter, Marlies 
en Hannah.  
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